A Phase 3 interventional study of 13 valent pneumococcal conjugate vaccine and 13 valent pneumococcal conjugate vaccine in Influenza, sponsored by Pfizer. Completed at 41 sites in United States. Open to participants aged 50 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-09.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Influenza, Human by Pfizer — 1 open to participants now, 2 under way, none of them phase 3. Influenza, Human · Pfizer.
Among the 15 studies in Influenza, Human by Pfizer, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2007, is one of 2 in phase 3, and was the 1st registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →1 of the 15 studies in Influenza, Human by Pfizer is open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 50 Years to 59 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 2 · Phase 4 1
First in 2007; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,116 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 882 across the 11 interventional studies, 5,075 across the 4 observational. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Influenza, Human by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05160636PfizerA Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza | 2027-01-31 |
| NCT07431853PfizerA Study to Learn About mRNA Vaccines Against Influenza in Adults | 2027-06-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Influenza, Human by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years who are naive to 23-valent pneumococcal polysaccharide vaccine (23vPS), or when the vaccines are given 1 month apart. It will also evaluate the immune response to 13vPnC once per year for 4 years and then to a second dose of 13vPnC given 5 years after the first dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
arm 1 = TIV +13vPnC at visit 1, placebo at visit 2 then 13vPnC at year 5
Biological: 13 valent pneumococcal conjugate vaccine
arm 2 = TIV + placebo at visit 1, then 13vPnC at visit 2 and at year 5
Biological: 13 valent pneumococcal conjugate vaccine
TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
Also known as: 0.5 mL dose of TIV and 13vPnC at dose 1, 0.5 mL dose of of placebo at dose 2, and 0.5ml dose of 13vPnC at year 5 will be administered into left deltoid muscle
TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
Also known as: 0.5 mL dose of TIV and of placebo at dose 1 and 0.5 mL dose of 13vPnC at dose 2 and year 5 will be administered into left deltoid muscle
Percentage of Participants Achieving at Least 4-fold Increase in Titer for Concomitant Trivalent Inactivated Influenza Vaccine (TIV) Antigens 1 Month After Dose 1
Percentage of participants achieving at least 4-fold increase in titer for concomitant Trivalent Inactivated Influenza Vaccine (TIV) were measured by standard Hemagglutination Inhibition Assay (HAI) for the A/H1, A/H3, and B vaccine strains.Exact, unconditional, 2-sided, 95% confidence intervals (CI) on the difference in proportions (13vPnC+TIV - Placebo+TIV) was calculated. N(number of participants analyzed)=participants with a determinate antibody titer to the given concomitant vaccine antigen. n=participants who met the prespecified level for the given antigen.
Time frame: 1 month after Dose 1
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose at year 0 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: 1 month after 13vPnC Dose at year 0
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC (Year 5)
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 Month After 13vPnC (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: 1 month after 13vPnC (Year 5)
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) Before 13vPnC (Year 5) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Participants with immunogenicity data at both Year 5 endpoints.
Time frame: before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5)
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold-Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 5)
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before 13vPnC (Year 5) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. n=participants with valid and determinate assay results for the specified serotype from both before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
Time frame: before 13vPnC (Year 5), 1 month after 13vPnC re-vaccinated dose (Year 5)
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points.n=participants with valid and determinate assay results for the specified serotype for both 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
Time frame: 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to 1 Month After 13vPnC (Year 0)
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
Time frame: 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) Before 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points.
Time frame: before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5)
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 0)
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before13vPnC (Year 0) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
Time frame: before 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Before and 1 Month After 13vPnC (Year 0), 1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5)
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data before, 1 month after 13vPnC (Year 0), at Years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. n=participants with valid and determinate assay results for the specified serotype at before, 1 month after 13vPnC (Year 0), at Years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) blood draws.
Time frame: Before,1 month after 13vPnC (Year 0), 1, 2, 3, 4 years after initial vaccination (Year 0); before,1 month after 13vPnC (Year 5)
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC (Year 0),1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5) Relative to Before 13vPnC (Year 0)
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before to 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both the baseline and the various time points.
Time frame: Before, 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5)
Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) 1 Month After 13vPnC (Year 5)
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 1 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: 1 month after 13vPnC (Year 5)
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) Before 13vPnC (Year 5) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Participants in this population must have immunogenicity data at both Year 5 time points.
Time frame: before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5)
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 5)
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before 13vPnC (Year 5) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
Time frame: before 13vPnC (Year 5), 1 month after 13vPnC re-vaccinated dose (Year 5)
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) 1 Month After 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points
Time frame: 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to 1 Month After 13vPnC (Year 0)
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
Time frame: 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)
Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) Before 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points.
Time frame: before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5)
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 0)
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from Before 13vPnC (Year 0) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
Time frame: Before 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Before and 1 Month After 13vPnC (Year 0), 1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5)
Participants received either 0.5 mL dose of 13vPnC intramuscular injection into the deltoid muscle of the left arm along with 0.5-mL TIV intramuscular injection into the deltoid muscle of the right arm at Year 0 on Day 1(Dose1, 13vPnC+TIV), or placebo matched to 13vPnC intramuscular injection into the deltoid muscle of the left arm along with 0.5-mL TIV intramuscular injection into the deltoid muscle of the right arm at Year 0 on Day 1(Dose 1, placebo+TIV). Placebo matched to 13vPnC was administered 1 month after(Dose 2, placebo), or 13vPnC was administered 1 month after (Dose 2, 13vPnC).Participants were further followed-up for 1 month,then attended a 6-month follow-up visit for safety.Participants were then followed-up yearly for 4 years.Participants then received 0.5 mL dose of 13vPnC intramuscular injection into the deltoid muscle of the left arm 5 years after initial vaccination.Participants were further followed-up for 1 month, then attended a 6-month follow-up visit for safety.
Time frame: Before,1 month after 13vPnC (Year 0), 1, 2, 3, 4 years after initial vaccination (Year 0); before,1 month after 13vPnC (Year 5)
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC (Year 0),1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5) Relative to Before 13vPnC (Year 0)
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before to 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both the baseline and the various time points.
Time frame: Before, 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5)
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Dose 1 (Year 0)
Specific local reactions were prompted for each day,and reported using an electronic diary.Redness and Swelling were scaled as Any(redness present or swelling present);Mild(2.5 to 5.0 centimeters \[cm\]);Moderate(5.1 to 10.0 cm);Severe (\>10 cm). Pain at injection site was scaled as: Any (pain present); Mild (awareness of sign or symptom, but easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, with inability to do usual activity). Limitation of arm movement was scaled as Any(no limitation of arm movement);Mild(some limitation of arm movement);Moderate (unable to move arm above head but able to move arm above shoulder);Severe (unable to move arm above shoulder). Local reactions were measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.
Time frame: Within 14 days after Dose 1 (Year 0)
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Dose 2 (Year 0)
Specific local reactions were prompted for each day,and reported using an electronic diary.Redness and Swelling were scaled as Any(redness present or swelling present);Mild(2.5 to 5.0 centimeters \[cm\]);Moderate(5.1 to 10.0 cm);Severe (\>10 cm). Pain at injection site was scaled as: Any (pain present); Mild (awareness of sign or symptom, but easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, with inability to do usual activity). Limitation of arm movement was scaled as Any(no limitation of arm movement);Mild(some limitation of arm movement);Moderate (unable to move arm above head but able to move arm above shoulder);Severe (unable to move arm above shoulder). Local reactions were measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.
Time frame: Within 14 days after Dose 2 (Year 0)
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After 13vPnC (Year 5)
Specific local reactions were prompted for each day,and reported using an electronic diary.Redness and Swelling were scaled as Any(redness present or swelling present);Mild(2.5 to 5.0 centimeters \[cm\]);Moderate(5.1 to 10.0 cm);Severe (\>10 cm). Pain at injection site was scaled as: Any (pain present); Mild (awareness of sign or symptom, but easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, with inability to do usual activity). Limitation of arm movement was scaled as Any(no limitation of arm movement);Mild(some limitation of arm movement);Moderate (unable to move arm above head but able to move arm above shoulder);Severe (unable to move arm above shoulder).
Time frame: Within 14 days after 13vPnC (Year 5)
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Dose 1 (Year 0)
Percentage of participants who experienced specific systemic events (mild: 38.0 to 38.4 degrees Celsius \[C\], moderate: 38.5 to 38.9 degrees C, severe: 39.0 to 40.0 degrees C and potentially life threatening greater than \[\>\] 40.0 degrees C), chills, fatigue, headache, vomiting, decreased appetite, rash, new generalized muscle pain, aggravated generalized muscle pain, new generalized joint pain, and aggravated generalized joint pain prompted for each day were reported using an electronic diary.
Time frame: Within 14 days after Dose 1 (Year 0)
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Dose 2 (Year 0)
Percentage of participants who experienced specific systemic events (absent: 38.0 degrees Celsius \[C\], mild: 38.0 to 38.4 degrees C, moderate: 38.5 to 38.9 degrees C, severe: 39.0 to 40.0 degrees C and potentially life threatening \> 40.0 degrees C), chills, fatigue, headache, vomiting, decreased appetite, rash, new generalized muscle pain, aggravated generalized muscle pain, new generalized joint pain, and aggravated generalized joint pain prompted for each day were reported using an electronic diary.
Time frame: Within 14 days after Dose 2 (Year 0)
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After 13vPnC (Year 5)
Percentage of participants who experienced specific systemic events (Fever: \>= 38.0 degrees Celsius \[C\], mild: 38.0 to 38.4 degrees C, moderate: 38.5 to 38.9 degrees C, severe: 39.0 to 40.0 degrees C and potentially life threatening \> 40.0 degrees C), chills, fatigue, headache, vomiting, decreased appetite, rash, new generalized muscle pain, aggravated generalized muscle pain, new generalized joint pain, and aggravated generalized joint pain prompted for each day were reported using an electronic diary.
Time frame: Within 14 days after 13vPnC (Year 5)
Percentage of Participants Reporting Pre-specified Acute Pain Within 30 Minutes After Dose 1 (Year 0)
Acute pain was not prompted in the electronic diary however were recorded in a specific page of the case report form (CRF). Acute pain at injection site pain occurred within 30 minutes of vaccination and was scaled as: Any (pain present); Mild (easily tolerated); Moderate (discomfort interfering the usual activity); Severe (Incapacitating with inability to do usual activity). Acute pain was measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.
Time frame: Within 30 Minutes After Dose 1 (Year 0)
Percentage of Participants Reporting Pre-specified Acute Pain Within 30 Minutes After Dose 2 (Year 0)
Acute pain was not prompted in the electronic diary however were recorded in a specific page of the case report form (CRF). Acute pain at injection site pain occurred within 30 minutes of vaccination and was scaled as: Any (pain present); Mild (easily tolerated); Moderate (discomfort interfering the usual activity); Severe (Incapacitating with inability to do usual activity). Acute pain was measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.
Time frame: Within 30 Minutes After Dose 2 (Year 0)
Percentage of Participants Reporting Pre-specified Acute Pain Within 30 Minutes After 13vPnC (Year 5)
Acute pain was not prompted in the electronic diary however were recorded in a specific page of the case report form (CRF). Acute pain at injection site pain occurred within 30 minutes of vaccination and was scaled as: Any (pain present); Mild (easily tolerated); Moderate (discomfort interfering the usual activity); Severe (Incapacitating with inability to do usual activity).
Time frame: Within 30 Minutes After 13vPnC (Year 5)
Percentage of Participants With Serious Adverse Events (SAEs) or Non-serious Adverse Events (Non-SAEs)
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Non-serious AEs are AEs excluding SAEs. In Years 1-4, only deaths and withdrawals due to AEs or SAEs were to be recorded in the case report form.
Time frame: Signing of informed consent up to 194 days after re-vaccination at Year 5
| Milestone | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Started | 554 | 562 |
| Vaccinated dose 1 | 551 | 560 |
| Vaccinated dose 2 | 538 | 543 |
| Initially reported to complete year 0 | 531 | 529 |
| Completed | 533 | 533 |
| Not completed | 21 | 29 |
| Withdrew: Subject request | 8 | 11 |
| Withdrew: Lost to follow-up | 5 | 10 |
| Withdrew: Protocol violation | 2 | 5 |
| Withdrew: Other, unspecified | 3 | 1 |
| Withdrew: Investigator request | 2 | 0 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Failed to return | 0 | 1 |
| Milestone | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Started | 533 | 533 |
| Completed | 364 | 363 |
| Not completed | 169 | 170 |
| Withdrew: Adverse event | 5 | 1 |
| Withdrew: Death | 5 | 2 |
| Withdrew: Failed to return | 7 | 3 |
| Withdrew: Investigator request | 3 | 3 |
| Withdrew: Lost to follow-up | 55 | 56 |
| Withdrew: Other | 22 | 26 |
| Withdrew: Protocol violation | 18 | 22 |
| Withdrew: Subject request | 54 | 57 |
| Milestone | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Started | 364 | 363 |
| Vaccinated 13vpnc (year 5) | 364 | 363 |
| Completed 1 month follow-up | 363 | 359 |
| Completed 6 month follow-up | 361 | 351 |
| Completed | 361 | 351 |
| Not completed | 3 | 12 |
| Withdrew: Subject request | 0 | 1 |
| Withdrew: Failed to return | 1 | 4 |
| Withdrew: Lost to follow-up | 2 | 7 |
Percentage of participants achieving at least 4-fold increase in titer for concomitant Trivalent Inactivated Influenza Vaccine (TIV) were measured by standard Hemagglutination Inhibition Assay (HAI) for the A/H1, A/H3, and B vaccine strains.Exact, unconditional, 2-sided, 95% confidence intervals (CI) on the difference in proportions (13vPnC+TIV - Placebo+TIV) was calculated. N(number of participants analyzed)=participants with a determinate antibody titer to the given concomitant vaccine antigen. n=participants who met the prespecified level for the given antigen.
| percentage of participants | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| A/H1N1 strain (n=445,431) | 84.0 (80.6 to 87.0) | 81.2 (77.6 to 84.4) |
| A/H3N2 strain (n=377,369) | 71.1 (67.1 to 75.0) | 69.5 (65.4 to 73.4) |
| B strain (n=321,320) | 60.6 (56.3 to 64.8) | 60.3 (56.0 to 64.5) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose at year 0 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| microgram per milliliter (mcg/mL) | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Serotype 1 (n=292, 289) | 4.05 (3.41 to 4.81) | 5.45 (4.57 to 6.49) |
| Serotype 3 (n=290, 288) | 1.15 (1.02 to 1.29) | 1.46 (1.29 to 1.65) |
| Serotype 4 (n=290, 288) | 2.35 (2.00 to 2.77) | 3.41 (2.89 to 4.02) |
| Serotype 5 (n=293, 289) | 6.03 (5.16 to 7.05) | 7.18 (6.13 to 8.40) |
| Serotype 6A (n=293, 288) | 5.78 (5.02 to 6.64) | 6.70 (5.74 to 7.83) |
| Serotype 6B (n=292, 289) | 7.58 (6.54 to 8.78) | 10.09 (8.57 to 11.86) |
| Serotype 7F (n=293, 289) | 8.14 (7.07 to 9.38) | 10.57 (9.11 to 12.27) |
| Serotype 9V (n=293, 289) | 4.96 (4.32 to 5.70) | 6.97 (6.08 to 7.99) |
| Serotype 14 (n=294, 288) | 10.77 (9.04 to 12.82) | 14.05 (11.82 to 16.71) |
| Serotype 18C (n=293, 288) | 9.65 (8.32 to 11.19) | 13.49 (11.62 to 15.67) |
| Serotype 19A (n=294, 289) | 16.80 (14.75 to 19.14) | 18.84 (16.37 to 21.68) |
| Serotype 19F (n=291, 286) | 6.13 (5.21 to 7.22) | 7.13 (5.90 to 8.63) |
| Serotype 23F (n=294, 289) | 7.17 (6.06 to 8.49) | 8.54 (7.11 to 10.25) |
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 Month After 13vPnC (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| titers | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Serotype 1 (n=349,352 ) | 178 (150.6 to 210.1) | 168 (141.4 to 199.9) |
| Serotype 3(n=355, 352) | 59 (52.1 to 67.1) | 66 (57.7 to 75.0) |
| Serotype 4(n=357,350) | 1618 (1453.2 to 1801.5) | 1491 (1318.4 to 1685.8) |
| Serotype 5(n=350,353) | 267 (224.7 to 317.0) | 312 (266.2 to 366.6) |
| Serotype 6A(n=356,350) | 4266 (3752.0 to 4849.9) | 3994 (3442.0 to 4635.6) |
| Serotype 6B(n=354,351) | 3583 (3130.7 to 4101.8) | 3567 (3149.2 to 4040.9) |
| Serotype 7F(n=355,352) | 1636 (1459.8 to 1834.3) | 1803 (1624.6 to 2001.7) |
| Serotype 9V(n=353,347) | 1818 (1581.5 to 2090.6) | 1551 (1282.4 to 1875.8) |
| Serotype 14(n=355,350) | 1110 (993.2 to 1239.7) | 1107 (988.1 to 1240.1) |
| Serotype 18C(n=353,348) | 1800 (1571.8 to 2060.7) | 1738 (1485.4 to 2033.8) |
| Serotype 19A(n=354,352) | 913 (815.7 to 1022.9) | 890 (787.1 to 1006.5) |
| Serotype 19F(n=345,338) | 1202 (1030.9 to 1402.0) | 1140 (976.7 to 1330.3) |
| Serotype 23F(n=354,350) | 1837 (1562.6 to 2159.9) | 1820 (1552.0 to 2134.4) |
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Participants with immunogenicity data at both Year 5 endpoints.
| titers | All Participants |
|---|---|
| Serotype 1:Before 13vPnC (Year 5),(n=690) | 10 (8.7 to 10.7) |
| Serotype 1: After 13vPnC (Year 5),(n=690) | 173 (153.5 to 195.5) |
| Serotype 3: Before 13vPnC (Year 5),(n=699) | 8 (7.6 to 9.2) |
| Serotype 3: After 13vPnC (Year 5),(n=699) | 62 (56.6 to 68.0) |
| Serotype 4 : Before 13vPnC (Year 5),(n=667) | 88 (73.5 to 106.6) |
| Serotype 4 : After 13vPnC (Year 5),(n=667) | 1553 (1426.5 to 1691.4) |
| Serotype 5 : Before 13vPnC (Year 5),(n=694) | 16 (13.8 to 18.0) |
| Serotype 5 :After 13vPnC (Year 5),(n=694) | 290 (257.8 to 326.4) |
| Serotype 6A : Before 13vPnC (Year 5),(n=677) | 173 (144.5 to 206.8) |
| Serotype 6A : After 13vPnC (Year 5),(n=677) | 4072 (3684.3 to 4500.2) |
| Serotype 6B : Before 13vPnC (Year 5),(n=650) | 209 (174.0 to 252.1) |
| Serotype 6B : After 13vPnC (Year 5),(n=650) | 3504 (3181.3 to 3859.7) |
| Serotype 7F: Before 13vPnC (Year 5),(n=687) | 122 (100.9 to 147.7) |
| Serotype 7F: After 13vPnC (Year 5),(n=687) | 1697 (1569.0 to 1834.7) |
| Serotype 9V: Before 13vPnC (Year 5),(n=671) | 97 (78.1 to 119.5) |
| Serotype 9V: After 13vPnC (Year 5),(n=671) | 1669 (1479.9 to 1882.6) |
| Serotype 14: Before 13vPnC (Year 5),(n=678) | 289 (250.5 to 332.9) |
| Serotype 14: After 13vPnC (Year 5),(n=678) | 1096 (1011.1 to 1187.9) |
| Serotype 18C: Before 13vPnC (Year 5),(n=683) | 120 (100.5 to 143.6) |
| Serotype 18C: After 13vPnC (Year 5),(n=683) | 1748 (1573.5 to 1941.9) |
| Serotype 19A: Before 13vPnC (Year 5),(n=696) | 113 (99.0 to 127.9) |
| Serotype 19A: After 13vPnC (Year 5),(n=696) | 900 (827.1 to 978.4) |
| Serotype 19F: Before 13vPnC (Year 5),(n=649) | 38 (31.5 to 45.1) |
| Serotype 19F: After 13vPnC (Year 5),(n=649) | 1146 (1024.6 to 1282.9) |
| Serotype 23F: Before 13vPnC (Year 5),(n=685) | 50 (42.2 to 59.0) |
| Serotype 23F: After 13vPnC (Year 5),(n=685) | 1819 (1620.2 to 2043.0) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before 13vPnC (Year 5) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. n=participants with valid and determinate assay results for the specified serotype from both before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
| fold-rises | All Participants |
|---|---|
| Serotype 1 (n=690) | 18.0 (15.72 to 20.53) |
| Serotype 3(n=699) | 7.4 (6.70 to 8.19) |
| Serotype 4(n=667) | 17.6 (14.59 to 21.12) |
| Serotype 5 (n=694) | 18.4 (16.12 to 20.99) |
| Serotype 6A(n=677) | 23.6 (19.74 to 28.11) |
| Serotype 6B(n=650) | 16.7 (13.98 to 20.02) |
| Serotype 7F(n=687) | 13.9 (11.48 to 16.83) |
| Serotype 9V(n=671) | 17.3 (14.10 to 21.17) |
| Serotype 14(n=678) | 3.8 (3.32 to 4.34) |
| Serotype 18C(n=683) | 14.6 (12.27 to 17.25) |
| Serotype 19A(n=696) | 8.0 (7.07 to 9.04) |
| Serotype 19F(n=649) | 30.4 (25.47 to 36.34) |
| Serotype 23F(n=685) | 36.5 (30.84 to 43.12) |
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points.n=participants with valid and determinate assay results for the specified serotype for both 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
| titers | All Participants |
|---|---|
| Serotype 1:After 13vPnC (Year 0),(n=381) | 217 (184.0 to 255.0) |
| Serotype 1: After 13vPnC (Year 5),(n=381) | 183 (156.6 to 214.6) |
| Serotype 3: After 13vPnC (Year 0),(n=374) | 69 (60.0 to 78.7) |
| Serotype 3: After 13vPnC (Year 5),(n=374) | 61 (54.4 to 69.0) |
| Serotype 4 : After 13vPnC (Year 0),(n=382) | 1905 (1666.7 to 2177.5) |
| Serotype 4 : After 13vPnC (Year 5),(n=382) | 1589 (1426.0 to 1771.3) |
| Serotype 5 : After 13vPnC (Year 0),(n=374) | 129 (104.5 to 160.1) |
| Serotype 5 :After 13vPnC (Year 5),(n=374) | 300 (256.8 to 350.4) |
| Serotype 6A : After 13vPnC (Year 0),(n=390) | 2779 (2345.5 to 3293.0) |
| Serotype 6A : After 13vPnC (Year 5),(n=390) | 4196 (3677.1 to 4787.1) |
| Serotype 6B : After 13vPnC (Year 0),(n=380) | 3089 (2662.6 to 3584.8) |
| Serotype 6B : After 13vPnC (Year 5),(n=380) | 3541 (3158.7 to 3968.9) |
| Serotype 7F: After 13vPnC (Year 0),(n=372) | 2196 (1839.7 to 2620.3) |
| Serotype 7F: After 13vPnC (Year 5),(n=372) | 1768 (1596.9 to 1958.3) |
| Serotype 9V: After 13vPnC (Year 0),(n=387) | 1343 (1097.1 to 1643.7) |
| Serotype 9V: After 13vPnC (Year 5),(n=387) | 1768 (1501.6 to 2081.6) |
| Serotype 14: After 13vPnC (Year 0),(n=383) | 1169 (994.7 to 1374.1) |
| Serotype 14: After 13vPnC (Year 5),(n=383) | 1135 (1017.5 to 1265.1) |
| Serotype 18C: After 13vPnC (Year 0),(n=381) | 1728 (1420.9 to 2101.1) |
| Serotype 18C: After 13vPnC (Year 5),(n=381) | 1772 (1540.0 to 2038.3) |
| Serotype 19A: After 13vPnC (Year 0),(n=378) | 879 (769.0 to 1005.4) |
| Serotype 19A: After 13vPnC (Year 5),(n=378) | 858 (763.9 to 963.0) |
| Serotype 19F: After 13vPnC (Year 0),(n=369) | 472 (383.9 to 579.9) |
| Serotype 19F: After 13vPnC (Year 5),(n=369) | 1139 (982.7 to 1319.6) |
| Serotype 23F: After 13vPnC (Year 0),(n=368) | 494 (396.4 to 615.2) |
| Serotype 23F: After 13vPnC (Year 5),(n=368) | 1955 (1700.6 to 2246.7) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
| fold-rises | All Participants |
|---|---|
| Serotype 1 (n=381) | 0.8 (0.70 to 1.02) |
| Serotype 3(n=374) | 0.9 (0.79 to 1.01) |
| Serotype 4(n=382) | 0.8 (0.73 to 0.95) |
| Serotype 5 (n=374) | 2.3 (1.92 to 2.80) |
| Serotype 6A(n=390) | 1.5 (1.31 to 1.74) |
| Serotype 6B(n=380) | 1.1 (1.00 to 1.31) |
| Serotype 7F(n=372) | 0.8 (0.67 to 0.96) |
| Serotype 9V(n=387) | 1.3 (1.08 to 1.60) |
| Serotype 14(n=383) | 1.0 (0.83 to 1.13) |
| Serotype 18C(n=381) | 1.0 (0.86 to 1.22) |
| Serotype 19A(n=378) | 1.0 (0.88 to 1.08) |
| Serotype 19F(n=369) | 2.4 (2.01 to 2.90) |
| Serotype 23F(n=368) | 4.0 (3.26 to 4.80) |
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points.
| titers | All Participants |
|---|---|
| Serotype 1:Before 13vPnC (Year 0),(n=384) | 6 (5.6 to 6.9) |
| Serotype 1: After 13vPnC (Year 5),(n=384) | 171 (145.4 to 200.4) |
| Serotype 3: Before 13vPnC (Year 0),(n=380) | 6 (5.6 to 6.9) |
| Serotype 3: After 13vPnC (Year 5),(n=380) | 60 (53.0 to 67.8) |
| Serotype 4 : Before 13vPnC (Year 0),(n=310) | 22 (16.3 to 28.9) |
| Serotype 4 : After 13vPnC (Year 5),(n=310) | 1558 (1379.0 to 1761.0) |
| Serotype 5 : Before 13vPnC (Year 0),(n=370) | 5 (4.6 to 5.4) |
| Serotype 5 :After 13vPnC (Year 5),(n=370) | 284 (241.8 to 333.1) |
| Serotype 6A : Before 13vPnC (Year 0),(n=356) | 18 (14.3 to 23.1) |
| Serotype 6A : After 13vPnC (Year 5),(n=356) | 4072 (3533.5 to 4692.1) |
| Serotype 6B : Before 13vPnC (Year 0),(n=333) | 53 (38.7 to 71.6) |
| Serotype 6B : After 13vPnC (Year 5),(n=333) | 3341 (2930.6 to 3809.9) |
| Serotype 7F: Before 13vPnC (Year 0),(n=330) | 10 (7.7 to 12.2) |
| Serotype 7F: After 13vPnC (Year 5),(n=330) | 1818 (1624.0 to 2035.0) |
| Serotype 9V: Before 13vPnC (Year 0),(n=352) | 28 (21.3 to 37.5) |
| Serotype 9V: After 13vPnC (Year 5),(n=352) | 1725 (1451.1 to 2050.8) |
| Serotype 14: Before 13vPnC (Year 0),(n=369) | 67 (50.8 to 87.2) |
| Serotype 14: After 13vPnC (Year 5),(n=369) | 1164 (1041.9 to 1300.8) |
| Serotype 18C: Before 13vPnC (Year 0),(n=361) | 20 (15.7 to 25.2) |
| Serotype 18C: After 13vPnC (Year 5),(n=361) | 1824 (1579.7 to 2105.6) |
| Serotype 19A: Before 13vPnC (Year 0),(n=348) | 28 (22.6 to 33.8) |
| Serotype 19A: After 13vPnC (Year 5),(n=348) | 849 (749.6 to 961.0) |
| Serotype 19F: Before 13vPnC (Year 0),(n=377) | 14 (11.3 to 16.7) |
| Serotype 19F: After 13vPnC (Year 5),(n=377) | 1106 (954.7 to 1281.3) |
| Serotype 23F: Before 13vPnC (Year 0),(n=350) | 9 (7.2 to 10.2) |
| Serotype 23F: After 13vPnC (Year 5),(n=350) | 1851 (1590.3 to 2155.3) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before13vPnC (Year 0) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
| fold-rises | All Participants |
|---|---|
| Serotype 1 (n=384) | 27.5 (23.05 to 32.78) |
| Serotype 3(n=380) | 9.7 (8.34 to 11.19) |
| Serotype 4(n=310) | 71.8 (53.28 to 96.69) |
| Serotype 5 (n=370) | 57.0 (48.03 to 67.58) |
| Serotype 6A(n=356) | 224.1 (171.09 to 293.51) |
| Serotype 6B(n=333) | 63.5 (46.14 to 87.45) |
| Serotype 7F(n=330) | 188.0 (147.92 to 238.83) |
| Serotype 9V(n=352) | 61.0 (45.19 to 82.31) |
| Serotype 14(n=369) | 17.5 (13.40 to 22.86) |
| Serotype 18C(n=361) | 91.7 (71.33 to 117.84) |
| Serotype 19A(n=348) | 30.7 (24.99 to 37.77) |
| Serotype 19F(n=377) | 80.5 (64.90 to 99.92) |
| Serotype 23F(n=350) | 216.5 (172.97 to 270.87) |
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data before, 1 month after 13vPnC (Year 0), at Years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. n=participants with valid and determinate assay results for the specified serotype at before, 1 month after 13vPnC (Year 0), at Years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) blood draws.
| titers | All Participants |
|---|---|
| Serotype 1: Before 13vPnC dose Year 0 (n=92) | 6 (4.9 to 7.0) |
| Serotype 1: After 13vPnC dose at Year 0 (n=92) | 200 (143.5 to 278.0) |
| Serotype 1: Year 1 (n=125) | 19 (14.0 to 26.7) |
| Serotype 1: Year 2 (n=128) | 14 (10.1 to 18.2) |
| Serotype 1: Year 3 (n=128) | 11 (8.3 to 14.5) |
| Serotype 1: Year 4 (n=127) | 10 (7.4 to 12.4) |
| Serotype 1: Before 13vPnC dose Year 5 (n=126) | 10 (7.8 to 12.8) |
| Serotype 1: After 13vPnC dose at Year 5 (n=126) | 203 (158.5 to 260.6) |
| Serotype 3: Before 13vPnC dose Year 0 (n=90) | 6 (4.9 to 7.3) |
| Serotype 3: After 13vPnC dose Year 0 (n=91) | 63 (48.1 to 83.6) |
| Serotype 3: Year 1 (n=129) | 14 (10.7 to 17.2) |
| Serotype 3: Year 2 (n=129) | 12 (9.2 to 14.7) |
| Serotype 3: Year 3 (n=129) | 9 (7.1 to 10.7) |
| Serotype 3: Year 4 (n=128) | 9 (7.2 to 11.3) |
| Serotype 3: Before 13vPnC dose Year 5 (n=129) | 9 (7.3 to 11.7) |
| Serotype 3: After 13vPnC dose at Year 5 (n=128) | 55 (44.6 to 68.1) |
| Serotype 4: Before 13vPnC dose Year 0 (n=74) | 16 (8.8 to 27.3) |
| Serotype 4: After 13vPnC dose at Year 0 (n=91) | 1896 (1429.7 to 2514.2) |
| Serotype 4: Year 1 (n=126) | 442 (309.0 to 632.4) |
| Serotype 4: Year 2 (n=121) | 181 (117.1 to 278.7) |
| Serotype 4: Year 3 (n=125) | 137 (89.4 to 211.0) |
| Serotype 4: Year 4 (n=123) | 97 (62.2 to 151.5) |
| Serotype 4: Before 13vPnC dose Year 5 (n=125) | 92 (59.7 to 140.6) |
| Serotype 4: After 13vPnC dose at Year 5 (n=128) | 1574 (1340.7 to 1847.9) |
| Serotype 5: Before 13vPnC dose Year 0 (n=89) | 5 (4.1 to 5.2) |
| Serotype 5: After 13vPnC dose at Year 0 (n=93) | 145 (96.5 to 216.6) |
| Serotype 5: Year 1 (n=130) | 32 (22.8 to 43.7) |
| Serotype 5: Year 2 (n=128) | 20 (14.4 to 27.0) |
| Serotype 5: Year 3 (n=128) | 17 (12.3 to 23.0) |
| Serotype 5: Year 4 (n=128) | 14 (10.7 to 19.3) |
| Serotype 5: Before 13vPnC dose Year 5 (n=129) | 13 (9.9 to 17.8) |
| Serotype 5: After 13vPnC dose at Year 5 (n=128) | 273 (204.7 to 365.2) |
| Serotype 6A: Before 13vPnC dose Year 0 (n=87) | 16 (9.9 to 26.1) |
| Serotype 6A: After 13vPnC dose Year 0 (n=94) | 2158 (1456.8 to 3196.6) |
| Serotype 6A: Year 1 (n=126) | 748 (532.4 to 1051.3) |
| Serotype 6A: Year 2 (n=129) | 405 (275.0 to 595.8) |
| Serotype 6A: Year 3 (n=127) | 282 (187.7 to 424.1) |
| Serotype 6A: Year 4 (n=126) | 203 (134.6 to 306.1) |
| Serotype 6A: Before 13vPnC dose Year 5 (n=125) | 166 (107.5 to 255.3) |
| Serotype 6A: After 13vPnC dose Year 5 (n=129) | 3777 (2916.3 to 4891.2) |
| Serotype 6B: Before 13vPnC dose Year 0 (n=83) | 88 (46.7 to 165.8) |
| Serotype 6B: After 13vPnC dose Year 0 (n=93) | 2950 (2110.7 to 4123.5) |
| Serotype 6B: Year 1 (n=122) | 765 (562.2 to 1039.9) |
| Serotype 6B: Year 2 (n=121) | 505 (353.9 to 720.2) |
| Serotype 6B: Year 3 (n=120) | 373 (253.3 to 549.8) |
| Serotype 6B: Year 4 (n=115) | 326 (218.2 to 485.9) |
| Serotype 6B: Before 13vPnC dose Year 5 (n=123) | 229 (149.1 to 350.3) |
| Serotype 6B: After 13vPnC dose Year 5 (n=127) | 3804 (3216.1 to 4499.0) |
| Serotype 7F: Before 13vPnC dose Year 0 (n=80) | 13 (7.9 to 23.0) |
| Serotype 7F: After 13vPnC dose Year 0 (n=88) | 2265 (1563.6 to 3280.4) |
| Serotype 7F: Year 1 (n=129) | 515 (356.6 to 745.1) |
| Serotype 7F: Year 2 (n=128) | 279 (182.4 to 426.9) |
| Serotype 7F: Year 3 (n=125) | 253 (165.1 to 387.4) |
| Serotype 7F: Year 4 (n=127) | 175 (114.3 to 268.6) |
| Serotype 7F: Before 13vPnC dose Year 5 (n=124) | 155 (98.7 to 244.5) |
| Serotype 7F: After 13vPnC dose Year 5 (n=129) | 1932 (1585.5 to 2353.7) |
| Serotype 9V: Before 13vPnC dose Year 0 (n=88) | 17 (9.7 to 28.3) |
| Serotype 9V: After 13vPnC dose Year 0 (n=93) | 1202 (795.7 to 1816.4) |
| Serotype 9V: Year 1 (n=125) | 276 (173.2 to 440.3) |
| Serotype 9V: Year 2 (n=127) | 136 (83.4 to 221.5) |
| Serotype 9V: Year 3 (n=128) | 121 (75.2 to 194.7) |
| Serotype 9V: Year 4 (n=124) | 66 (39.8 to 108.7) |
| Serotype 9V: Before 13vPnC dose Year 5 (n=128) | 86 (53.1 to 139.9) |
| Serotype 9V: After 13vPnC dose Year 5 (n=127) | 1572 (1155.4 to 2139.2) |
| Serotype 14: Before 13vPnC dose Year 0 (n=87) | 74 (41.7 to 130.1) |
| Serotype 14: After 13vPnC dose Year 0 (n=90) | 1436 (1036.7 to 1989.0) |
| Serotype 14: Year 1 (n=124) | 541 (394.3 to 741.1) |
| Serotype 14: Year 2 (n=125) | 446 (326.5 to 609.0) |
| Serotype 14: Year 3 (n=124) | 416 (302.8 to 571.3) |
| Serotype 14: Year 4 (n=125) | 341 (241.9 to 481.4) |
| Serotype 14: Before 13vPnC dose Year 5 (n=127) | 335 (244.8 to 457.6) |
| Serotype 14: After 13vPnC dose Year 5 (n=128) | 1238 (1046.4 to 1464.2) |
| Serotype 18C: Before 13vPnC dose Year 0 (n=82) | 18 (11.4 to 29.2) |
| Serotype 18C: After 13vPnC dose Year 0 (n=92) | 1189 (766.6 to 1843.2) |
| Serotype 18C: Year 1 (n=127) | 301 (206.2 to 440.4) |
| Serotype 18C: Year 2 (n=123) | 170 (115.2 to 251.6) |
| Serotype 18C: Year 3 (n=129) | 115 (76.7 to 171.2) |
| Serotype 18C: Year 4 (n=126) | 102 (67.6 to 154.9) |
| Serotype 18C: Before 13vPnC dose Year 5 (n=127) | 99 (65.9 to 148.1) |
| Serotype 18C: After 13vPnC dose Year 5 (n=127) | 1580 (1289.0 to 1937.4) |
| Serotype 19A: Before 13vPnC dose Year 0 (n=84) | 24 (15.7 to 37.1) |
| Serotype 19A: After 13vPnC dose Year 0 (n=92) | 727 (551.4 to 957.4) |
| Serotype 19A: Year 1 (n=130) | 193 (145.9 to 255.4) |
| Serotype 19A: Year 2 (n=127) | 135 (100.4 to 181.9) |
| Serotype 19A: Year 3 (n=129) | 105 (76.6 to 143.3) |
| Serotype 19A: Year 4 (n=129) | 97 (72.0 to 131.6) |
| Serotype 19A: Before 13vPnC dose Year 5 (n=130) | 97 (71.7 to 132.3) |
| Serotype 19A: After 13vPnC dose Year 5 (n=128) | 874 (729.8 to 1046.1) |
| Serotype 19F: Before 13vPnC dose Year 0 (n=94) | 14 (9.3 to 21.1) |
| Serotype 19F: After 13vPnC dose Year 0 (n=91) | 448 (298.8 to 670.5) |
| Serotype 19F: Year 1 (n=124) | 85 (55.7 to 131.0) |
| Serotype 19F: Year 2 (n=128) | 44 (28.9 to 67.3) |
| Serotype 19F: Year 3 (n=128) | 35 (23.0 to 54.4) |
| Serotype 19F: Year 4 (n=125) | 29 (19.2 to 44.0) |
| Serotype 19F: Before 13vPnC dose Year 5 (n=125) | 24 (15.9 to 36.1) |
| Serotype 19F: After 13vPnC dose Year 5 (n=125) | 1112 (882.3 to 1400.5) |
| Serotype 23F: Before 13vPnC dose Year 0 (n=84) | 9 (6.1 to 13.3) |
| Serotype 23F: After 13vPnC dose Year 0 (n=89) | 396 (242.7 to 646.6) |
| Serotype 23F: Year 1 (n=127) | 116 (78.9 to 171.6) |
| Serotype 23F: Year 2 (n=124) | 95 (64.1 to 141.0) |
| Serotype 23F: Year 3 (n=128) | 60 (40.4 to 88.0) |
| Serotype 23F: Year 4 (n=127) | 54 (36.8 to 78.6) |
| Serotype 23F: Before 13vPnC dose Year 5 (n=127) | 48 (33.0 to 71.1) |
| Serotype 23F: After 13vPnC dose Year 5 (n=128) | 1642 (1263.2 to 2133.5) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before to 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both the baseline and the various time points.
| fold-rises | All Participants |
|---|---|
| Serotype 1:After 13vPnC dose at Year 0 (n=89) | 34.0 (24.24 to 47.66) |
| Serotype 1: Year 1 (n= 90) | 3.5 (2.45 to 5.00) |
| Serotype 1: Year 2 (n=91) | 2.4 (1.72 to 3.26) |
| Serotype 1: Year 3 (n= 92) | 1.8 (1.38 to 2.47) |
| Serotype 1: Year 4 (n= 90) | 1.6 (1.24 to 2.09) |
| Serotype 1: Before 13vPnC dose Year 5 (n=89) | 1.7 (1.26 to 2.16) |
| Serotype 1: After 13vPnC dose at Year 5 (n=89) | 39.3 (28.69 to 53.81) |
| Serotype 3: After 13vPnC dose at Year 0 (n=87) | 10.4 (7.65 to 14.23) |
| Serotype 3: Year 1 (n=89) | 2.0 (1.59 to 2.58) |
| Serotype 3: Year 2 (n=89) | 1.6 (1.29 to 2.01) |
| Serotype 3: Year 3 (n=89) | 1.3 (1.04 to 1.56) |
| Serotype 3: Year 4 (n=89) | 1.4 (1.15 to 1.76) |
| Serotype 3: Before 13vPnC dose Year 5 (n=90) | 1.5 (1.14 to 1.86) |
| Serotype 3: After 13vPnC dose at Year 5 (n=89) | 9.1 (6.93 to 12.07) |
| Serotype 4: After 13vPnC dose at Year 0 (n=72) | 118.9 (65.63 to 215.39) |
| Serotype 4: Year 1 (n=74) | 21.3 (11.90 to 38.06) |
| Serotype 4: Year 2 (n=71) | 8.3 (4.66 to 14.95) |
| Serotype 4: Year 3 (n=70) | 6.5 (3.75 to 11.15) |
| Serotype 4: Year 4 (n=71) | 4.6 (2.73 to 7.63) |
| Serotype 4: Before 13vPnC dose Year 5 (n=71) | 4.7 (2.80 to 7.74) |
| Serotype 4: After 13vPnC dose at Year 5 (n=73) | 98.7 (54.38 to 179.10) |
| Serotype 5: After 13vPnC dose at Year 0 (n=87) | 29.5 (19.21 to 45.45) |
| Serotype 5: Year 1 (n=89) | 6.1 (4.18 to 8.91) |
| Serotype 5: Year 2 (n=88) | 3.7 (2.57 to 5.40) |
| Serotype 5: Year 3 (n=88) | 2.9 (2.05 to 4.19) |
| Serotype 5: Year 4 (n=88) | 2.6 (1.84 to 3.59) |
| Serotype 5: Before 13vPnC dose Year 5 (n=88) | 2.3 (1.67 to 3.29) |
| Serotype 5: After 13vPnC dose at Year 5 (n=87) | 60.6 (42.73 to 86.06) |
| Serotype 6A: After 13vPnC dose Year 0 (n=86) | 126.8 (69.14 to 232.51) |
| Serotype 6A: Year 1 (n=85) | 38.3 (22.35 to 65.79) |
| Serotype 6A: Year 2 (n=87) | 21.9 (12.98 to 36.99) |
| Serotype 6A: Year 3 (n=86) | 14.8 (8.83 to 24.79) |
| Serotype 6A: Year 4 (n=85) | 11.7 (7.00 to 19.62) |
| Serotype 6A: Before 13vPnC dose Year 5 (n=85) | 9.2 (5.40 to 15.81) |
| Serotype 6A: After 13vPnC dose Year 5 (n=86) | 219.2 (123.97 to 387.54) |
| Serotype 6B: After 13vPnC dose Year 0 (n=81) | 33.3 (17.17 to 64.74) |
| Serotype 6B: Year 1 (n=78) | 8.9 (4.88 to 16.21) |
| Serotype 6B: Year 2 (n=78) | 5.7 (3.18 to 10.14) |
| Serotype 6B: Year 3 (n=77) | 4.3 (2.33 to 7.98) |
| Serotype 6B: Year 4 (n=73) | 3.3 (1.91 to 5.75) |
| Serotype 6B: Before 13vPnC dose Year 5 (n=81) | 2.9 (1.63 to 5.28) |
| Serotype 6B: After 13vPnC dose Year 5 (n=81) | 38.8 (19.92 to 75.61) |
| Serotype 7F: After 13vPnC dose Year 0 (n=75) | 168.6 (88.78 to 320.29) |
| Serotype 7F: Year 1 (n=80) | 37.1 (19.84 to 69.34) |
| Serotype 7F: Year 2 (n=78) | 18.7 (10.16 to 34.57) |
| Serotype 7F: Year 3 (n=76) | 17.8 (9.69 to 32.66) |
| Serotype 7F: Year 4 (n=78) | 10.4 (5.69 to 18.93) |
| Serotype 7F: Before 13vPnC dose Year 5 (n=77) | 8.4 (4.57 to 15.56) |
| Serotype 7F: After 13vPnC dose Year 5 (n=80) | 163.6 (95.30 to 280.70) |
| Serotype 9V: After 13vPnC dose Year 0 (n=86) | 68.2 (37.54 to 123.92) |
| Serotype 9V: Year 1 (n=86) | 12.2 (6.94 to 21.55) |
| Serotype 9V: Year 2 (n=87) | 5.6 (3.30 to 9.63) |
| Serotype 9V: Year 3 (n=88) | 5.3 (3.20 to 8.80) |
| Serotype 9V: Year 4 (n=84) | 3.0 (1.79 to 5.00) |
| Serotype 9V: Before 13vPnC dose Year 5 (n=87) | 3.8 (2.19 to 6.66) |
| Serotype 9V: After 13vPnC dose Year 5 (n=86) | 99.3 (54.99 to 179.41) |
| Serotype 14: After 13vPnC dose Year 0 (n=83) | 22.4 (12.42 to 40.22) |
| Serotype 14: Year 1 (n=84) | 7.3 (4.35 to 12.22) |
| Serotype 14: Year 2 (n=85) | 6.2 (3.86 to 10.11) |
| Serotype 14: Year 3 (n=82) | 5.2 (3.12 to 8.80) |
| Serotype 14: Year 4 (n=84) | 5.5 (3.26 to 9.42) |
| Serotype 14: Before 13vPnC dose Year 5 (n=86) | 4.7 (2.85 to 7.86) |
| Serotype 14: After 13vPnC dose Year 5 (n=86) | 19.9 (11.37 to 35.00) |
| Serotype 18C: After 13vPnC dose Year 0 (n=79) | 58.2 (31.53 to 107.35) |
| Serotype 18C: Year 1 (n=81) | 12.3 (7.45 to 20.29) |
| Serotype 18C: Year 2 (n=81) | 6.2 (3.73 to 10.34) |
| Serotype 18C: Year 3 (n=81) | 4.5 (2.82 to 7.30) |
| Serotype 18C: Year 4 (n=79) | 3.9 (2.46 to 6.22) |
| Serotype 18C: Before 13vPnC dose Year 5 (n=81) | 3.9 (2.40 to 6.28) |
| Serotype 18C: After 13vPnC dose Year 5 (n=79) | 82.7 (50.04 to 136.70) |
| Serotype 19A: After 13vPnC dose Year 0 (n=81) | 28.4 (18.04 to 44.69) |
| Serotype 19A: Year 1 (n=84) | 7.3 (4.72 to 11.16) |
| Serotype 19A: Year 2 (n=82) | 5.4 (3.55 to 8.18) |
| Serotype 19A: Year 3 (n=84) | 4.1 (2.72 to 6.10) |
| Serotype 19A: Year 4 (n=84) | 3.7 (2.42 to 5.61) |
| Serotype 19A: Before 13vPnC dose Year 5 (n=84) | 3.8 (2.45 to 5.99) |
| Serotype 19A: After 13vPnC dose Year 5 (n=83) | 36.4 (23.40 to 56.57) |
| Serotype 19F: After 13vPnC dose Year 0 (n=90) | 32.8 (20.67 to 51.98) |
| Serotype 19F: Year 1 (n=91) | 6.3 (4.08 to 9.86) |
| Serotype 19F: Year 2 (n=93) | 3.9 (2.58 to 6.02) |
| Serotype 19F: Year 3 (n=92) | 2.7 (1.76 to 4.09) |
| Serotype 19F: Year 4 (n=91) | 2.4 (1.62 to 3.56) |
| Serotype 19F: Before 13vPnC dose Year 5 (n=90) | 1.9 (1.26 to 2.83) |
| Serotype 19F: After 13vPnC dose Year 5 (n=89) | 81.6 (52.36 to 127.08) |
| Serotype 23F: After 13vPnC dose Year 0 (n=79) | 41.2 (23.36 to 72.69) |
| Serotype 23F: Year 1 (n=84) | 12.6 (7.69 to 20.62) |
| Serotype 23F: Year 2 (n=81) | 9.6 (5.81 to 15.78) |
| Serotype 23F: Year 3 (n=84) | 6.6 (4.13 to 10.41) |
| Serotype 23F: Year 4 (n=84) | 5.8 (3.68 to 9.26) |
| Serotype 23F: Before 13vPnC dose Year 5 (n=83) | 5.3 (3.31 to 8.53) |
| Serotype 23F: After 13vPnC dose Year 5 (n=82) | 194.0 (115.99 to 324.32) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 1 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| microgram per milliliter(mcg/mL) | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Serotype 1 (n=357, 345) | 5.92 (5.33 to 6.57) | 5.83 (5.20 to 6.55) |
| Serotype 3(n=343, 338) | 0.69 (0.62 to 0.76) | 0.72 (0.65 to 0.80) |
| Serotype 4(n=357,345) | 4.90 (4.42 to 5.44) | 4.77 (4.22 to 5.39) |
| Serotype 5(n=357,345) | 7.49 (6.71 to 8.35) | 8.02 (7.16 to 8.99) |
| Serotype 6A(n=357,345) | 13.59 (12.01 to 15.39) | 13.45 (11.67 to 15.51) |
| Serotype 6B(n=355,345) | 20.18 (17.74 to 22.96) | 21.76 (18.97 to 24.96) |
| Serotype 7F(n=357,345) | 8.48 (7.72 to 9.30) | 8.70 (7.91 to 9.58) |
| Serotype 9V(n=357,345) | 5.91 (5.37 to 6.51) | 6.35 (5.74 to 7.02) |
| Serotype 14(n=357,345) | 15.57 (13.94 to 17.39) | 16.39 (14.70 to 18.28) |
| Serotype 18C(n=357,345) | 7.77 (7.06 to 8.55) | 8.46 (7.58 to 9.44) |
| Serotype 19A(n=357,345) | 16.77 (15.09 to 18.64) | 17.97 (16.14 to 20.01) |
| Serotype 19F(n=357,345) | 16.83 (14.86 to 19.06) | 18.18 (15.77 to 20.96) |
| Serotype 23F(n=357,345) | 18.15 (15.87 to 20.76) | 20.25 (17.57 to 23.32) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Participants in this population must have immunogenicity data at both Year 5 time points.
| mcg/mL | All Participants |
|---|---|
| Serotype 1:Before 13vPnC (Year 5),(n=665) | 1.27 (1.16 to 1.40) |
| Serotype 1: After 13vPnC (Year 5),(n=665) | 5.87 (5.42 to 6.36) |
| Serotype 3: Before 13vPnC (Year 5),(n=623) | 0.33 (0.30 to 0.37) |
| Serotype 3: After 13vPnC (Year 5),(n=623) | 0.71 (0.65 to 0.76) |
| Serotype 4 : Before 13vPnC (Year 5),(n=663) | 0.67 (0.60 to 0.74) |
| Serotype 4 : After 13vPnC (Year 5),(n=663) | 4.83 (4.45 to 5.24) |
| Serotype 5 : Before 13vPnC (Year 5),(n=671) | 2.65 (2.45 to 2.87) |
| Serotype 5 :After 13vPnC (Year 5),(n=671) | 7.76 (7.16 to 8.41) |
| Serotype 6A : Before 13vPnC (Year 5),(n=671) | 2.52 (2.33 to 2.73) |
| Serotype 6A : After 13vPnC (Year 5),(n=671) | 13.51 (12.28 to 14.86) |
| Serotype 6B : Before 13vPnC (Year 5),(n=668) | 3.12 (2.86 to 3.41) |
| Serotype 6B : After 13vPnC (Year 5),(n=668) | 21.04 (19.12 to 23.16) |
| Serotype 7F: Before 13vPnC (Year 5),(n=671) | 2.52 (2.31 to 2.76) |
| Serotype 7F: After 13vPnC (Year 5),(n=671) | 8.72 (8.16 to 9.33) |
| Serotype 9V: Before 13vPnC (Year 5),(n=672) | 2.11 (1.96 to 2.28) |
| Serotype 9V: After 13vPnC (Year 5),(n=672) | 6.14 (5.71 to 6.59) |
| Serotype 14: Before 13vPnC (Year 5),(n=672) | 5.17 (4.69 to 5.70) |
| Serotype 14: After 13vPnC (Year 5),(n=672) | 16.26 (15.03 to 17.58) |
| Serotype 18C: Before 13vPnC (Year 5),(n=672) | 2.55 (2.34 to 2.78) |
| Serotype 18C: After 13vPnC (Year 5),(n=672) | 8.10 (7.52 to 8.72) |
| Serotype 19A: Before 13vPnC (Year 5),(n=671) | 5.47 (5.07 to 5.89) |
| Serotype 19A: After 13vPnC (Year 5),(n=671) | 17.29 (16.03 to 18.65) |
| Serotype 19F: Before 13vPnC (Year 5),(n=664) | 2.24 (2.02 to 2.47) |
| Serotype 19F: After 13vPnC (Year 5),(n=664) | 17.73 (16.10 to 19.53) |
| Serotype 23F: Before 13vPnC (Year 5),(n=671) | 2.50 (2.29 to 2.73) |
| Serotype 23F: After 13vPnC (Year 5),(n=671) | 19.23 (17.45 to 21.20) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before 13vPnC (Year 5) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
| fold-rises | All Participants |
|---|---|
| Serotype 1 (n=665) | 4.62 (4.22 to 5.05) |
| Serotype 3(n=623) | 2.11 (1.99 to 2.24) |
| Serotype 4(n=663) | 7.24 (6.60 to 7.95) |
| Serotype 5 (n=671) | 2.93 (2.75 to 3.12) |
| Serotype 6A(n=671) | 5.35 (4.92 to 5.82) |
| Serotype 6B(n=668) | 6.74 (6.19 to 7.34) |
| Serotype 7F(n=671) | 3.46 (3.20 to 3.74) |
| Serotype 9V(n=672) | 2.90 (2.74 to 3.08) |
| Serotype 14(n=672) | 3.14 (2.89 to 3.42) |
| Serotype 18C(n=672) | 3.18 (2.96 to 3.41) |
| Serotype 19A(n=671) | 3.16 (2.95 to 3.39) |
| Serotype 19F(n=664) | 7.93 (7.21 to 8.72) |
| Serotype 23F(n=671) | 7.69 (7.05 to 8.39) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points
| mcg/mL | All Participants |
|---|---|
| Serotype 1:After 13vPnC (Year 0),(n=389) | 4.77 (4.10 to 5.54) |
| Serotype 1: After 13vPnC (Year 5),(n=389) | 5.88 (5.32 to 6.50) |
| Serotype 3: After 13vPnC (Year 0),(n=378) | 1.26 (1.13 to 1.40) |
| Serotype 3: After 13vPnC (Year 5),(n=378) | 0.74 (0.67 to 0.81) |
| Serotype 4 : After 13vPnC (Year 0),(n=387) | 2.90 (2.51 to 3.36) |
| Serotype 4 : After 13vPnC (Year 5),(n=387) | 5.13 (4.64 to 5.68) |
| Serotype 5 : After 13vPnC (Year 0),(n=390) | 6.52 (5.72 to 7.44) |
| Serotype 5 :After 13vPnC (Year 5),(n=390) | 8.25 (7.40 to 9.20) |
| Serotype 6A : After 13vPnC (Year 0),(n=390) | 6.13 (5.41 to 6.94) |
| Serotype 6A : After 13vPnC (Year 5),(n=390) | 13.52 (11.94 to 15.31) |
| Serotype 6B : After 13vPnC (Year 0),(n=390) | 8.87 (7.77 to 10.14) |
| Serotype 6B : After 13vPnC (Year 5),(n=390) | 20.70 (18.31 to 23.39) |
| Serotype 7F: After 13vPnC (Year 0),(n=390) | 9.24 (8.16 to 10.47) |
| Serotype 7F: After 13vPnC (Year 5),(n=390) | 8.40 (7.68 to 9.19) |
| Serotype 9V: After 13vPnC (Year 0),(n=391) | 5.83 (5.17 to 6.56) |
| Serotype 9V: After 13vPnC (Year 5),(n=391) | 6.07 (5.53 to 6.65) |
| Serotype 14: After 13vPnC (Year 0),(n=391) | 11.98 (10.33 to 13.91) |
| Serotype 14: After 13vPnC (Year 5),(n=391) | 15.04 (13.57 to 16.66) |
| Serotype 18C: After 13vPnC (Year 0),(n=390) | 11.64 (10.20 to 13.29) |
| Serotype 18C: After 13vPnC (Year 5),(n=390) | 8.25 (7.47 to 9.12) |
| Serotype 19A: After 13vPnC (Year 0),(n=391) | 17.43 (15.51 to 19.59) |
| Serotype 19A: After 13vPnC (Year 5),(n=391) | 18.48 (16.68 to 20.48) |
| Serotype 19F: After 13vPnC (Year 0),(n=388) | 6.56 (5.66 to 7.60) |
| Serotype 19F: After 13vPnC (Year 5),(n=388) | 18.26 (16.14 to 20.66) |
| Serotype 23F: After 13vPnC (Year 0),(n=391) | 8.03 (6.91 to 9.32) |
| Serotype 23F: After 13vPnC (Year 5),(n=391) | 20.17 (17.81 to 22.83) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
| fold-rises | All Participants |
|---|---|
| Serotype 1 (n=389) | 1.23 (1.07 to 1.42) |
| Serotype 3(n=378) | 0.59 (0.54 to 0.64) |
| Serotype 4(n=387) | 1.77 (1.56 to 2.01) |
| Serotype 5 (n=390) | 1.26 (1.14 to 1.41) |
| Serotype 6A(n=390) | 2.21 (1.97 to 2.47) |
| Serotype 6B(n=390) | 2.33 (2.08 to 2.61) |
| Serotype 7F(n=390) | 0.91 (0.81 to 1.02) |
| Serotype 9V(n=391) | 1.04 (0.95 to 1.14) |
| Serotype 14(n=391) | 1.25 (1.10 to 1.43) |
| Serotype 18C(n=390) | 0.71 (0.64 to 0.79) |
| Serotype 19A(n=391) | 1.06 (0.96 to 1.17) |
| Serotype 19F(n=388) | 2.78 (2.44 to 3.17) |
| Serotype 23F(n=391) | 2.51 (2.23 to 2.83) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points.
| mcg/mL | All Participants |
|---|---|
| Serotype 1:Before 13vPnC (Year 0),(n=380) | 0.44 (0.38 to 0.50) |
| Serotype 1: After 13vPnC (Year 5),(n=380) | 5.86 (5.29 to 6.48) |
| Serotype 3: Before 13vPnC (Year 0),(n=368) | 0.47 (0.42 to 0.53) |
| Serotype 3: After 13vPnC (Year 5),(n=368) | 0.74 (0.67 to 0.81) |
| Serotype 4 : Before 13vPnC (Year 0),(n=373) | 0.22 (0.19 to 0.26) |
| Serotype 4 : After 13vPnC (Year 5),(n=373) | 5.21 (4.71 to 5.77) |
| Serotype 5 : Before 13vPnC (Year 0),(n=387) | 1.79 (1.65 to 1.95) |
| Serotype 5 :After 13vPnC (Year 5),(n=387) | 8.32 (7.46 to 9.27) |
| Serotype 6A : Before 13vPnC (Year 0),(n=386) | 1.56 (1.42 to 1.71) |
| Serotype 6A : After 13vPnC (Year 5),(n=386) | 13.63 (12.03 to 15.45) |
| Serotype 6B : Before 13vPnC (Year 0),(n=383) | 1.76 (1.58 to 1.96) |
| Serotype 6B : After 13vPnC (Year 5),(n=383) | 21.09 (18.66 to 23.84) |
| Serotype 7F: Before 13vPnC (Year 0),(n=384) | 0.70 (0.62 to 0.79) |
| Serotype 7F: After 13vPnC (Year 5),(n=384) | 8.41 (7.70 to 9.19) |
| Serotype 9V: Before 13vPnC (Year 0),(n=387) | 0.87 (0.79 to 0.96) |
| Serotype 9V: After 13vPnC (Year 5),(n=387) | 6.07 (5.53 to 6.66) |
| Serotype 14: Before 13vPnC (Year 0),(n=389) | 1.95 (1.69 to 2.26) |
| Serotype 14: After 13vPnC (Year 5),(n=389) | 14.98 (13.51 to 16.61) |
| Serotype 18C: Before 13vPnC (Year 0),(n=388) | 0.82 (0.72 to 0.94) |
| Serotype 18C: After 13vPnC (Year 5),(n=388) | 8.24 (7.45 to 9.11) |
| Serotype 19A: Before 13vPnC (Year 0),(n=388) | 2.92 (2.66 to 3.22) |
| Serotype 19A: After 13vPnC (Year 5),(n=388) | 18.52 (16.71 to 20.53) |
| Serotype 19F: Before 13vPnC (Year 0),(n=371) | 1.17 (1.03 to 1.33) |
| Serotype 19F: After 13vPnC (Year 5),(n=371) | 18.68 (16.46 to 21.19) |
| Serotype 23F: Before 13vPnC (Year 0),(n=382) | 0.97 (0.86 to 1.09) |
| Serotype 23F: After 13vPnC (Year 5),(n=382) | 20.53 (18.14 to 23.23) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from Before 13vPnC (Year 0) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.
| fold-rises | All Participants |
|---|---|
| Serotype 1 (n=380) | 13.37 (11.66 to 15.33) |
| Serotype 3(n=368) | 1.57 (1.43 to 1.73) |
| Serotype 4(n=373) | 23.59 (20.21 to 27.55) |
| Serotype 5 (n=387) | 4.64 (4.17 to 5.16) |
| Serotype 6A(n=386) | 8.74 (7.63 to 10.00) |
| Serotype 6B(n=383) | 11.96 (10.46 to 13.68) |
| Serotype 7F(n=384) | 11.96 (10.53 to 13.57) |
| Serotype 9V(n=387) | 6.97 (6.29 to 7.73) |
| Serotype 14(n=389) | 7.68 (6.62 to 8.92) |
| Serotype 18C(n=388) | 10.04 (8.84 to 11.40) |
| Serotype 19A(n=388) | 6.33 (5.66 to 7.09) |
| Serotype 19F(n=371) | 15.95 (13.69 to 18.57) |
| Serotype 23F(n=382) | 21.18 (18.50 to 24.25) |
Participants received either 0.5 mL dose of 13vPnC intramuscular injection into the deltoid muscle of the left arm along with 0.5-mL TIV intramuscular injection into the deltoid muscle of the right arm at Year 0 on Day 1(Dose1, 13vPnC+TIV), or placebo matched to 13vPnC intramuscular injection into the deltoid muscle of the left arm along with 0.5-mL TIV intramuscular injection into the deltoid muscle of the right arm at Year 0 on Day 1(Dose 1, placebo+TIV). Placebo matched to 13vPnC was administered 1 month after(Dose 2, placebo), or 13vPnC was administered 1 month after (Dose 2, 13vPnC).Participants were further followed-up for 1 month,then attended a 6-month follow-up visit for safety.Participants were then followed-up yearly for 4 years.Participants then received 0.5 mL dose of 13vPnC intramuscular injection into the deltoid muscle of the left arm 5 years after initial vaccination.Participants were further followed-up for 1 month, then attended a 6-month follow-up visit for safety.
| mcg/mL | All Participants |
|---|---|
| Serotype 1: Before 13vPnC dose Year 0 (n=79) | 0.37 (0.28 to 0.49) |
| Serotype 1: After 13vPnC dose at Year 0 (n=83) | 4.53 (3.33 to 6.18) |
| Serotype 1: Year 1 (n=119) | 1.96 (1.55 to 2.48) |
| Serotype 1: Year 2 (n=124) | 1.56 (1.25 to 1.96) |
| Serotype 1: Year 3 (n=126) | 1.34 (1.08 to 1.66) |
| Serotype 1: Year 4 (n=125) | 1.32 (1.06 to 1.63) |
| Serotype 1: Before 13vPnC dose Year 5 (n=125) | 1.18 (0.95 to 1.47) |
| Serotype 1: After 13vPnC dose at Year 5 (n=125) | 6.08 (5.20 to 7.11) |
| Serotype 3: Before 13vPnC dose Year 0 (n=81) | 0.42 (0.33 to 0.53) |
| Serotype 3: After 13vPnC dose Year 0 (n=82) | 1.15 (0.92 to 1.44) |
| Serotype 3: Year 1 (n=115) | 0.37 (0.30 to 0.46) |
| Serotype 3: Year 2 (n=122) | 0.34 (0.27 to 0.42) |
| Serotype 3: Year 3 (n=119) | 0.30 (0.25 to 0.37) |
| Serotype 3: Year 4 (n=117) | 0.31 (0.25 to 0.38) |
| Serotype 3: Before 13vPnC dose Year 5 (n=117) | 0.30 (0.24 to 0.38) |
| Serotype 3: After 13vPnC dose at Year 5 (n=121) | 0.66 (0.55 to 0.79) |
| Serotype 4: Before 13vPnC dose Year 0 (n=80) | 0.19 (0.14 to 0.25) |
| Serotype 4: After 13vPnC dose at Year 0 (n=82) | 2.41 (1.74 to 3.35) |
| Serotype 4: Year 1 (n=118) | 0.98 (0.77 to 1.26) |
| Serotype 4: Year 2 (n=123) | 0.77 (0.61 to 0.98) |
| Serotype 4: Year 3 (n=125) | 0.67 (0.53 to 0.85) |
| Serotype 4: Year 4 (n=125) | 0.64 (0.50 to 0.82) |
| Serotype 4: Before 13vPnC dose Year 5 (n=122) | 0.58 (0.46 to 0.74) |
| Serotype 4: After 13vPnC dose at Year 5 (n=125) | 4.62 (3.92 to 5.45) |
| Serotype 5: Before 13vPnC dose Year 0 (n=82) | 1.40 (1.17 to 1.69) |
| Serotype 5: After 13vPnC dose at Year 0 (n=83) | 5.80 (4.40 to 7.64) |
| Serotype 5: Year 1 (n=118) | 3.10 (2.58 to 3.73) |
| Serotype 5: Year 2 (n=124) | 2.62 (2.19 to 3.14) |
| Serotype 5: Year 3 (n=126) | 2.40 (2.01 to 2.86) |
| Serotype 5: Year 4 (n=125) | 2.44 (2.05 to 2.91) |
| Serotype 5: Before 13vPnC dose Year 5 (n=125) | 2.41 (2.01 to 2.88) |
| Serotype 5: After 13vPnC dose at Year 5 (n=125) | 7.14 (5.95 to 8.57) |
| Serotype 6A: Before 13vPnC dose Year 0 (n=82) | 1.34 (1.09 to 1.66) |
| Serotype 6A: After 13vPnC dose Year 0 (n=83) | 5.74 (4.29 to 7.68) |
| Serotype 6A: Year 1 (n=119) | 3.64 (2.95 to 4.50) |
| Serotype 6A: Year 2 (n=124) | 3.10 (2.54 to 3.79) |
| Serotype 6A: Year 3 (n=126) | 2.76 (2.26 to 3.38) |
| Serotype 6A: Year 4 (n=126) | 2.74 (2.26 to 3.32) |
| Serotype 6A: Before 13vPnC dose Year 5 (n=125) | 2.63 (2.16 to 3.21) |
| Serotype 6A: After 13vPnC dose Year 5 (n=125) | 14.31 (11.43 to 17.93) |
| Serotype 6B: Before 13vPnC dose Year 0 (n=81) | 1.56 (1.23 to 1.97) |
| Serotype 6B: After 13vPnC dose Year 0 (n=83) | 8.24 (6.17 to 11.00) |
| Serotype 6B: Year 1 (n=119) | 4.96 (3.97 to 6.20) |
| Serotype 6B: Year 2 (n=124) | 3.97 (3.23 to 4.88) |
| Serotype 6B: Year 3 (n=126) | 3.58 (2.91 to 4.41) |
| Serotype 6B: Year 4 (n=126) | 3.53 (2.88 to 4.31) |
| Serotype 6B: Before 13vPnC dose Year 5 (n=125) | 3.18 (2.56 to 3.93) |
| Serotype 6B: After 13vPnC dose Year 5 (n=124) | 21.61 (17.55 to 26.60) |
| Serotype 7F: Before 13vPnC dose Year 0 (n=81) | 0.64 (0.51 to 0.81) |
| Serotype 7F: After 13vPnC dose Year 0 (n=83) | 9.14 (6.78 to 12.31) |
| Serotype 7F: Year 1 (n=119) | 3.82 (3.05 to 4.79) |
| Serotype 7F: Year 2 (n=124) | 3.10 (2.46 to 3.89) |
| Serotype 7F: Year 3 (n=126) | 2.58 (2.08 to 3.19) |
| Serotype 7F: Year 4 (n=126) | 2.55 (2.05 to 3.18) |
| Serotype 7F: Before 13vPnC dose Year 5 (n=124) | 2.36 (1.90 to 2.93) |
| Serotype 7F: After 13vPnC dose Year 5 (n=125) | 8.05 (6.68 to 9.71) |
| Serotype 9V: Before 13vPnC dose Year 0 (n=80) | 0.77 (0.63 to 0.95) |
| Serotype 9V: After 13vPnC dose Year 0 (n=83) | 4.58 (3.62 to 5.81) |
| Serotype 9V: Year 1 (n=119) | 2.84 (2.39 to 3.37) |
| Serotype 9V: Year 2 (n=124) | 2.37 (1.99 to 2.81) |
| Serotype 9V: Year 3 (n=126) | 2.16 (1.82 to 2.56) |
| Serotype 9V: Year 4 (n=126) | 2.09 (1.76 to 2.47) |
| Serotype 9V: Before 13vPnC dose Year 5 (n=125) | 1.97 (1.67 to 2.34) |
| Serotype 9V: After 13vPnC dose Year 5 (n=125) | 5.99 (5.14 to 6.98) |
| Serotype 14: Before 13vPnC dose Year 0 (n=82) | 2.21 (1.64 to 2.97) |
| Serotype 14: After 13vPnC dose Year 0 (n=83) | 14.48 (10.72 to 19.57) |
| Serotype 14: Year 1 (n=119) | 7.71 (6.07 to 9.80) |
| Serotype 14: Year 2 (n=124) | 6.82 (5.47 to 8.49) |
| Serotype 14: Year 3 (n=126) | 5.71 (4.50 to 7.25) |
| Serotype 14: Year 4 (n=126) | 5.31 (4.22 to 6.69) |
| Serotype 14: Before 13vPnC dose Year 5 (n=125) | 5.30 (4.20 to 6.70) |
| Serotype 14: After 13vPnC dose Year 5 (n=125) | 16.85 (14.07 to 20.18) |
| Serotype 18C: Before 13vPnC dose Year 0 (n=82) | 0.81 (0.62 to 1.07) |
| Serotype 18C: After 13vPnC dose Year 0 (n=83) | 8.11 (6.03 to 10.89) |
| Serotype 18C: Year 1 (n=119) | 3.45 (2.85 to 4.18) |
| Serotype 18C: Year 2 (n=124) | 2.82 (2.35 to 3.38) |
| Serotype 18C: Year 3 (n=126) | 2.38 (1.98 to 2.86) |
| Serotype 18C: Year 4 (n=126) | 2.44 (2.07 to 2.88) |
| Serotype 18C: Before 13vPnC dose Year 5 (n=125) | 2.26 (1.89 to 2.71) |
| Serotype 18C: After 13vPnC dose Year 5 (n=125) | 6.94 (5.92 to 8.12) |
| Serotype 19A: Before 13vPnC dose Year 0 (n=82) | 2.57 (2.13 to 3.11) |
| Serotype 19A: After 13vPnC dose Year 0 (n=83) | 14.11 (11.28 to 17.64) |
| Serotype 19A: Year 1 (n=119) | 6.95 (5.78 to 8.35) |
| Serotype 19A: Year 2 (n=124) | 6.13 (5.19 to 7.25) |
| Serotype 19A: Year 3 (n=126) | 5.60 (4.73 to 6.63) |
| Serotype 19A: Year 4 (n=126) | 5.47 (4.65 to 6.45) |
| Serotype 19A: Before 13vPnC dose Year 5 (n=125) | 5.11 (4.32 to 6.05) |
| Serotype 19A: After 13vPnC dose Year 5 (n=125) | 15.77 (13.25 to 18.78) |
| Serotype 19F: Before 13vPnC dose Year 0 (n=78) | 0.99 (0.75 to 1.29) |
| Serotype 19F: After 13vPnC dose Year 0 (n=83) | 5.64 (4.16 to 7.66) |
| Serotype 19F: Year 1 (n=118) | 2.87 (2.29 to 3.60) |
| Serotype 19F: Year 2 (n=121) | 2.55 (2.05 to 3.16) |
| Serotype 19F: Year 3 (n=124) | 2.28 (1.84 to 2.83) |
| Serotype 19F: Year 4 (n=125) | 2.26 (1.83 to 2.81) |
| Serotype 19F: Before 13vPnC dose Year 5 (n=123) | 2.10 (1.66 to 2.66) |
| Serotype 19F: After 13vPnC dose Year 5 (n=125) | 17.37 (14.23 to 21.20) |
| Serotype 23F: Before 13vPnC dose Year 0 (n=80) | 0.97 (0.73 to 1.30) |
| Serotype 23F: After 13vPnC dose Year 0 (n=83) | 6.06 (4.38 to 8.39) |
| Serotype 23F: Year 1 (n=118) | 3.65 (2.96 to 4.51) |
| Serotype 23F: Year 2 (n=123) | 2.93 (2.40 to 3.57) |
| Serotype 23F: Year 3 (n=126) | 2.67 (2.19 to 3.25) |
| Serotype 23F: Year 4 (n=126) | 2.62 (2.16 to 3.17) |
| Serotype 23F: Before 13vPnC dose Year 5 (n=125) | 2.50 (2.05 to 3.04) |
| Serotype 23F: After 13vPnC dose Year 5 (n=125) | 16.95 (13.73 to 20.91) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before to 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both the baseline and the various time points.
| fold-rises | All Participants |
|---|---|
| Serotype 1:After 13vPnC dose at Year 0 (n=79) | 12.50 (9.25 to 16.90) |
| Serotype 1: Year 1 (n=72) | 5.64 (4.32 to 7.35) |
| Serotype 1: Year 2 (n=75) | 4.73 (3.73 to 6.00) |
| Serotype 1: Year 3 (n=76) | 4.01 (3.15 to 5.11) |
| Serotype 1: Year 4 (n=75) | 3.79 (3.00 to 4.78) |
| Serotype 1: Before 13vPnC dose Year 5 (n=76) | 3.41 (2.72 to 4.28) |
| Serotype 1: After 13vPnC dose at Year 5 (n=77) | 15.25 (11.63 to 19.99) |
| Serotype 3: After 13vPnC dose at Year 0 (n=80) | 2.69 (2.21 to 3.28) |
| Serotype 3: Year 1 (n=73) | 0.89 (0.74 to 1.07) |
| Serotype 3: Year 2 (n=77) | 0.77 (0.66 to 0.90) |
| Serotype 3: Year 3 (n= 77) | 0.72 (0.62 to 0.84) |
| Serotype 3: Year 4 (n=72) | 0.69 (0.58 to 0.82) |
| Serotype 3: Before 13vPnC dose Year 5 (n=74) | 0.65 (0.56 to 0.76) |
| Serotype 3: After 13vPnC dose at Year 5 (n=78) | 1.51 (1.22 to 1.87) |
| Serotype 4: After 13vPnC dose at Year 0 (n=79) | 12.81 (9.27 to 17.70) |
| Serotype 4: Year 1 (n=74) | 6.00 (4.52 to 7.96) |
| Serotype 4: Year 2 (n=75) | 4.63 (3.51 to 6.10) |
| Serotype 4: Year 3 (n=77) | 4.12 (3.11 to 5.46) |
| Serotype 4: Year 4 (n=76) | 3.82 (2.90 to 5.03) |
| Serotype 4: Before 13vPnC dose Year 5 (n=77) | 3.41 (2.61 to 4.46) |
| Serotype 4: After 13vPnC dose at Year 5 (n=78) | 24.99 (18.07 to 34.56) |
| Serotype 5: After 13vPnC dose at Year 0 (n=82) | 4.21 (3.27 to 5.43) |
| Serotype 5: Year 1 (n=75) | 2.43 (2.02 to 2.92) |
| Serotype 5: Year 2 (n=78) | 2.05 (1.74 to 2.42) |
| Serotype 5: Year 3 (n=79) | 1.86 (1.58 to 2.18) |
| Serotype 5: Year 4 (n=78) | 1.84 (1.58 to 2.16) |
| Serotype 5: Before 13vPnC dose Year 5 (n=79) | 1.74 (1.47 to 2.08) |
| Serotype 5: After 13vPnC dose at Year 5 (n=80) | 5.38 (4.26 to 6.80) |
| Serotype 6A: After 13vPnC dose Year 0 (n=82) | 4.32 (3.35 to 5.57) |
| Serotype 6A: Year 1 (n=75) | 2.66 (2.15 to 3.27) |
| Serotype 6A: Year 2 (n=78) | 2.15 (1.80 to 2.57) |
| Serotype 6A: Year 3 (n=79) | 1.96 (1.64 to 2.34) |
| Serotype 6A: Year 4 (n=78) | 1.91 (1.62 to 2.26) |
| Serotype 6A: Before 13vPnC dose Year 5 (n=79) | 1.74 (1.46 to 2.07) |
| Serotype 6A: After 13vPnC dose Year 5 (n=80) | 10.18 (7.50 to 13.82) |
| Serotype 6B: After 13vPnC dose Year 0 (n=81) | 5.50 (4.09 to 7.39) |
| Serotype 6B: Year 1 (n=74) | 3.24 (2.53 to 4.15) |
| Serotype 6B: Year 2 (n=77) | 2.59 (2.13 to 3.16) |
| Serotype 6B: Year 3 (n=78) | 2.36 (1.94 to 2.88) |
| Serotype 6B: Year 4 (n=77) | 2.20 (1.83 to 2.65) |
| Serotype 6B: Before 13vPnC dose Year 5 (n=78) | 1.92 (1.57 to 2.36) |
| Serotype 6B: After 13vPnC dose Year 5 (n=79) | 12.82 (9.51 to 17.26) |
| Serotype 7F: After 13vPnC dose Year 0 (n=81) | 14.60 (10.96 to 19.46) |
| Serotype 7F: Year 1 (n=75) | 6.28 (4.91 to 8.03) |
| Serotype 7F: Year 2 (n=77) | 5.03 (3.97 to 6.39) |
| Serotype 7F: Year 3 (n=78) | 4.12 (3.30 to 5.15) |
| Serotype 7F: Year 4 (n=77) | 3.87 (3.11 to 4.80) |
| Serotype 7F: Before 13vPnC dose Year 5 (n=77) | 3.63 (2.92 to 4.50) |
| Serotype 7F: After 13vPnC dose Year 5 (n=79) | 11.65 (8.85 to 15.33) |
| Serotype 9V: After 13vPnC dose Year 0 (n=80) | 5.81 (4.68 to 7.22) |
| Serotype 9V: Year 1 (n=75) | 3.34 (2.80 to 3.98) |
| Serotype 9V: Year 2 (n=77) | 2.90 (2.44 to 3.45) |
| Serotype 9V: Year 3 (n=77) | 2.60 (2.20 to 3.09) |
| Serotype 9V: Year 4 (n=76) | 2.51 (2.14 to 2.94) |
| Serotype 9V: Before 13vPnC dose Year 5 (n=77) | 2.24 (1.89 to 2.65) |
| Serotype 9V: After 13vPnC dose Year 5 (n=78) | 7.35 (5.92 to 9.12) |
| Serotype 14: After 13vPnC dose Year 0 (n=82) | 6.47 (4.43 to 9.46) |
| Serotype 14: Year 1 (n=75) | 4.00 (2.86 to 5.59) |
| Serotype 14: Year 2 (n=78) | 3.54 (2.61 to 4.82) |
| Serotype 14: Year 3 (n=79) | 3.10 (2.28 to 4.22) |
| Serotype 14: Year 4 (n=78) | 2.84 (2.10 to 3.83) |
| Serotype 14: Before 13vPnC dose Year 5 (n=79) | 2.68 (1.96 to 3.67) |
| Serotype 14: After 13vPnC dose Year 5 (n=80) | 6.94 (5.11 to 9.42) |
| Serotype 18C: After 13vPnC dose Year 0 (n=82) | 9.86 (7.35 to 13.23) |
| Serotype 18C: Year 1 (n=75) | 4.56 (3.54 to 5.87) |
| Serotype 18C: Year 2 (n=78) | 3.74 (2.95 to 4.74) |
| Serotype 18C: Year 3 (n=79) | 3.11 (2.42 to 4.01) |
| Serotype 18C: Year 4 (n=78) | 2.97 (2.38 to 3.71) |
| Serotype 18C: Before 13vPnC dose Year 5 (n=79) | 2.77 (2.21 to 3.46) |
| Serotype 18C: After 13vPnC dose Year 5 (n=80) | 8.73 (6.64 to 11.48) |
| Serotype 19A: After 13vPnC dose Year 0 (n=82) | 5.52 (4.44 to 6.87) |
| Serotype 19A: Year 1 (n=75) | 2.69 (2.21 to 3.28) |
| Serotype 19A: Year 2 (n=78) | 2.39 (2.00 to 2.85) |
| Serotype 19A: Year 3 (n=79) | 2.14 (1.80 to 2.54) |
| Serotype 19A: Year 4 (n=78) | 2.06 (1.75 to 2.42) |
| Serotype 19A: Before 13vPnC dose Year 5 (n=79) | 1.87 (1.59 to 2.21) |
| Serotype 19A: After 13vPnC dose Year 5 (n=80) | 6.00 (4.78 to 7.52) |
| Serotype 19F: After 13vPnC dose Year 0 (n=78) | 6.02 (4.68 to 7.75) |
| Serotype 19F: Year 1 (n=71) | 3.39 (2.66 to 4.32) |
| Serotype 19F: Year 2 (n=72) | 2.74 (2.22 to 3.39) |
| Serotype 19F: Year 3 (n=76) | 2.42 (1.97 to 2.98) |
| Serotype 19F: Year 4 (n=75) | 2.24 (1.85 to 2.72) |
| Serotype 19F: Before 13vPnC dose Year 5 (n=74) | 2.01 (1.59 to 2.55) |
| Serotype 19F: After 13vPnC dose Year 5 (n=76) | 18.16 (13.04 to 25.30) |
| Serotype 23F: After 13vPnC dose Year 0 (n=80) | 6.65 (5.03 to 8.78) |
| Serotype 23F: Year 1 (n=73) | 3.57 (2.90 to 4.40) |
| Serotype 23F: Year 2 (n=75) | 3.09 (2.53 to 3.78) |
| Serotype 23F: Year 3 (n=77) | 2.93 (2.35 to 3.65) |
| Serotype 23F: Year 4 (n=76) | 2.77 (2.23 to 3.46) |
| Serotype 23F: Before 13vPnC dose Year 5 (n=77) | 2.48 (2.01 to 3.07) |
| Serotype 23F: After 13vPnC dose Year 5 (n=78) | 16.52 (12.29 to 22.22) |
Specific local reactions were prompted for each day,and reported using an electronic diary.Redness and Swelling were scaled as Any(redness present or swelling present);Mild(2.5 to 5.0 centimeters \[cm\]);Moderate(5.1 to 10.0 cm);Severe (\>10 cm). Pain at injection site was scaled as: Any (pain present); Mild (awareness of sign or symptom, but easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, with inability to do usual activity). Limitation of arm movement was scaled as Any(no limitation of arm movement);Mild(some limitation of arm movement);Moderate (unable to move arm above head but able to move arm above shoulder);Severe (unable to move arm above shoulder). Local reactions were measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.
| percentage of participants | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Redness: Any (n=282,263) | 16.3 | 3.0 |
| Redness: Mild (n=281,262) | 15.7 | 2.7 |
| Redness: Moderate (n=265,258) | 4.2 | 0.4 |
| Redness: Severe (n=262,257) | 0.4 | 0.0 |
| Swelling: Any (n=288,263) | 18.4 | 3.0 |
| Swelling: Mild (n=288,263) | 17.0 | 3.0 |
| Swelling: Moderate (n=263,257) | 5.7 | 0.0 |
| Swelling: Severe (262,257) | 0.4 | 0.0 |
| Pain: Any (n=469,321) | 86.8 | 37.1 |
| Pain: Mild (n=459, 318) | 82.8 | 35.2 |
| Pain: Moderate (n=324,261) | 39.2 | 4.2 |
| Pain: Severe (n=267,258) | 4.1 | 0.4 |
| Limitation of arm movement:Any(317,270) | 35.6 | 8.9 |
| Limitation of arm movement:Mild(n=310,268) | 32.6 | 8.2 |
| Limitation of arm movement: Moderate(n=269,259) | 5.2 | 1.2 |
| Limitation of arm movement:Severe(n=266,258) | 3.4 | 0.8 |
Specific local reactions were prompted for each day,and reported using an electronic diary.Redness and Swelling were scaled as Any(redness present or swelling present);Mild(2.5 to 5.0 centimeters \[cm\]);Moderate(5.1 to 10.0 cm);Severe (\>10 cm). Pain at injection site was scaled as: Any (pain present); Mild (awareness of sign or symptom, but easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, with inability to do usual activity). Limitation of arm movement was scaled as Any(no limitation of arm movement);Mild(some limitation of arm movement);Moderate (unable to move arm above head but able to move arm above shoulder);Severe (unable to move arm above shoulder). Local reactions were measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.
| percentage of participants | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Redness: Any (n=238,257) | 1.7 | 12.1 |
| Redness: Mild (n=238,255) | 1.7 | 10.2 |
| Redness: Moderate (n=236,248) | 0.0 | 5.6 |
| Redness: Severe (n=236,242) | 0.0 | 1.2 |
| Swelling: Any (n=242,265) | 4.5 | 14.7 |
| Swelling: Mild (n=242,260) | 4.5 | 12.3 |
| Swelling: Moderate (n=236,249) | 0.4 | 6.4 |
| Swelling: Severe (236,241) | 0.0 | 0.4 |
| Pain: Any (n=294,453) | 32.0 | 84.5 |
| Pain: Mild (n=290, 431) | 30.7 | 82.1 |
| Pain: Moderate (n=243,319) | 4.5 | 41.1 |
| Pain: Severe (n=236,248) | 0.0 | 4.8 |
| Limitation of arm movement:Any(248,318) | 9.3 | 42.5 |
| Limitation of arm movement:Mild(n=248,316) | 9.3 | 41.1 |
| Limitation of arm movement: Moderate(n=236,248) | 0.4 | 5.2 |
| Limitation of arm movement:Severe(n=236,244) | 0.0 | 2.9 |
Specific local reactions were prompted for each day,and reported using an electronic diary.Redness and Swelling were scaled as Any(redness present or swelling present);Mild(2.5 to 5.0 centimeters \[cm\]);Moderate(5.1 to 10.0 cm);Severe (\>10 cm). Pain at injection site was scaled as: Any (pain present); Mild (awareness of sign or symptom, but easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, with inability to do usual activity). Limitation of arm movement was scaled as Any(no limitation of arm movement);Mild(some limitation of arm movement);Moderate (unable to move arm above head but able to move arm above shoulder);Severe (unable to move arm above shoulder).
| percentage of participants | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Redness: Any (n=216,215) | 15.7 | 20.9 |
| Redness: Mild (n=215,212) | 14.0 | 17.5 |
| Redness: Moderate (n=210,211) | 7.1 | 12.3 |
| Redness: Severe (n=205,202) | 1.5 | 0.5 |
| Swelling: Any (n=224,216) | 18.8 | 18.1 |
| Swelling: Mild (n=223,214) | 17.5 | 15.9 |
| Swelling: Moderate (n=211,208) | 7.1 | 9.6 |
| Swelling: Severe (205,203) | 0.0 | 1.0 |
| Pain: Any (n=313,306) | 79.2 | 79.4 |
| Pain: Mild (n=297, 299) | 76.4 | 74.9 |
| Pain: Moderate (n=248,235) | 32.7 | 34.9 |
| Pain: Severe (n=206,205) | 4.4 | 3.4 |
| Limitation of arm movement:Any(233,224) | 23.2 | 26.3 |
| Limitation of arm movement:Mild(n=233,219) | 22.3 | 22.8 |
| Limitation of arm movement: Moderate(n=208,206) | 2.9 | 3.9 |
| Limitation of arm movement:Severe(n=206,206) | 1.9 | 3.4 |
Percentage of participants who experienced specific systemic events (mild: 38.0 to 38.4 degrees Celsius \[C\], moderate: 38.5 to 38.9 degrees C, severe: 39.0 to 40.0 degrees C and potentially life threatening greater than \[\>\] 40.0 degrees C), chills, fatigue, headache, vomiting, decreased appetite, rash, new generalized muscle pain, aggravated generalized muscle pain, new generalized joint pain, and aggravated generalized joint pain prompted for each day were reported using an electronic diary.
| percentage of participants | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Fever: >=38 but <38.5 degree C(n=261,259) | 1.5 | 1.2 |
| Fever: >=38.5 but <39 degree C(n=262,257) | 1.5 | 0.0 |
| Fever: >=39 but =<40.0 degree C(n=261,257) | 0.4 | 0.0 |
| Fever:>40.0 degree C (n=261,257) | 0.0 | 0.4 |
| Fatigue(n=389,359) | 58.1 | 52.4 |
| Headache(n=399,382) | 65.9 | 56.5 |
| Chills(n=306,291) | 31.4 | 21.0 |
| Rash(n=278,264) | 12.6 | 4.9 |
| Vomiting(n=266,262) | 5.3 | 3.4 |
| Decreased appetite(n=315,301) | 30.2 | 22.6 |
| New generalized muscle pain(n=385,326) | 65.5 | 37.7 |
| Aggravated generalized muscle pain(n=314,294) | 34.7 | 24.1 |
| New generalized joint pain(n=309,296) | 33.0 | 24.7 |
| Aggravated generalized joint pain(n=292,284) | 21.2 | 18.0 |
Percentage of participants who experienced specific systemic events (absent: 38.0 degrees Celsius \[C\], mild: 38.0 to 38.4 degrees C, moderate: 38.5 to 38.9 degrees C, severe: 39.0 to 40.0 degrees C and potentially life threatening \> 40.0 degrees C), chills, fatigue, headache, vomiting, decreased appetite, rash, new generalized muscle pain, aggravated generalized muscle pain, new generalized joint pain, and aggravated generalized joint pain prompted for each day were reported using an electronic diary.
| percentage of participants | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Fever: >=38 but <38.5 degree C(n=238,241) | 1.3 | 1.2 |
| Fever: >=38.5 but <39 degree C(n=239,240) | 1.3 | 0.8 |
| Fever: >=39 but =<40 degree (n=236,240) | 0.4 | 0.4 |
| Fever: >40.0 degree C(n=237,240) | 0.4 | 0.0 |
| Fatigue (n=316,338) | 43.7 | 51.8 |
| Headache (n=334,338) | 48.2 | 50.9 |
| Chills (n=273,276) | 20.5 | 24.6 |
| Rash (n=246,252) | 6.1 | 9.5 |
| Vomiting (n=247,247) | 6.9 | 6.1 |
| Decreased appetite(n=270,279) | 20.4 | 25.8 |
| New generalized muscle pain(n=288,350) | 28.5 | 59.1 |
| Aggravated generalized muscle pain(n=268,305) | 18.7 | 36.7 |
| New generalized joint pain(n=268,285) | 20.5 | 27.4 |
| Aggravated generalized joint pain(n=264,282) | 15.5 | 23.8 |
Percentage of participants who experienced specific systemic events (Fever: \>= 38.0 degrees Celsius \[C\], mild: 38.0 to 38.4 degrees C, moderate: 38.5 to 38.9 degrees C, severe: 39.0 to 40.0 degrees C and potentially life threatening \> 40.0 degrees C), chills, fatigue, headache, vomiting, decreased appetite, rash, new generalized muscle pain, aggravated generalized muscle pain, new generalized joint pain, and aggravated generalized joint pain prompted for each day were reported using an electronic diary.
| percentage of participants | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Fever: >= 38.0 degrees C (n=206,209) | 2.4 | 5.3 |
| Fever: >=38 but <38.5 degree C(n=205,206) | 1.0 | 2.4 |
| Fever: >=38.5 but <39 degree C(n=206,204) | 0.5 | 2.0 |
| Fever: >=39 but =<40 degree C(n=205,202) | 0.0 | 0.0 |
| Fever: >40 degree C(n=205,204) | 1.0 | 1.5 |
| Fatigue(n=263,251) | 43.7 | 45.8 |
| Headache(n=256,248) | 46.9 | 51.2 |
| Chills(n=229,217) | 23.1 | 22.1 |
| Rash(n=209,210) | 7.7 | 13.8 |
| Vomiting(n=206,207) | 3.4 | 7.2 |
| Decreased appetite(n=226,227) | 20.4 | 22.0 |
| New generalized muscle pain(n=266,253) | 47.7 | 51.0 |
| Aggravated generalized muscle pain(n=241,223) | 29.9 | 27.4 |
| New generalized joint pain(n=219,219) | 19.2 | 21.9 |
| Aggravated generalized joint pain(n=218,214) | 17.4 | 18.2 |
Acute pain was not prompted in the electronic diary however were recorded in a specific page of the case report form (CRF). Acute pain at injection site pain occurred within 30 minutes of vaccination and was scaled as: Any (pain present); Mild (easily tolerated); Moderate (discomfort interfering the usual activity); Severe (Incapacitating with inability to do usual activity). Acute pain was measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.
| percentage of participants | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Acute pain (Dose 1):Mild | 6.7 | 6.3 |
| Acute pain (Dose 1):Moderate | 0.0 | 0.0 |
| Acute pain (Dose 1):Severe | 0.0 | 0.0 |
| Acute pain (Dose 1): Any | 6.7 | 6.3 |
Acute pain was not prompted in the electronic diary however were recorded in a specific page of the case report form (CRF). Acute pain at injection site pain occurred within 30 minutes of vaccination and was scaled as: Any (pain present); Mild (easily tolerated); Moderate (discomfort interfering the usual activity); Severe (Incapacitating with inability to do usual activity). Acute pain was measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.
| percentage of participants | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Acute pain (Dose 2):Mild | 5.9 | 6.4 |
| Acute pain (Dose 2):Moderate | 0.0 | 0.0 |
| Acute pain (Dose 2):Severe | 0.0 | 0.0 |
| Acute pain (Dose 2):Any | 5.9 | 6.4 |
Acute pain was not prompted in the electronic diary however were recorded in a specific page of the case report form (CRF). Acute pain at injection site pain occurred within 30 minutes of vaccination and was scaled as: Any (pain present); Mild (easily tolerated); Moderate (discomfort interfering the usual activity); Severe (Incapacitating with inability to do usual activity).
| percentage of participants | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| Acute pain at injection site:Mild | 3.8 | 4.4 |
| Acute pain at injection site:Moderate | 0.3 | 0.0 |
| Acute pain at injection site:Severe | 0.0 | 0.0 |
| Acute pain at injection site: Any | 4.1 | 4.4 |
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Non-serious AEs are AEs excluding SAEs. In Years 1-4, only deaths and withdrawals due to AEs or SAEs were to be recorded in the case report form.
| percentage of participants | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) |
|---|---|---|
| SAEs at Dose 1 (Year 0) (n=551,560) | 0.7 | 0.9 |
| SAEs at Dose 2 (Year 0) (n=538,543) | 0.6 | 1.1 |
| SAEs at 6-month follow-up (Year 0) (n=538,543) | 3.3 | 1.8 |
| SAEs at Years 1-4(n=536,542) | 1.5 | 0.6 |
| SAEs at 13vPnC (Year 5)(n=364,363) | 0.5 | 0.6 |
| SAEs at 6-month follow-up (Year 5)(n=364,363) | 0.5 | 0.5 |
| non-SAEs at Dose 1 (Year 0)(n=551,560) | 0.5 | 0.8 |
| non-SAEs at Dose 2 (Year 0)(n=538,543) | 16.2 | 13.2 |
| non-SAEs at 6-month follow-up (Year 0)(n=538,543) | 11.3 | 10.9 |
| non-SAEs at Years 1-4(n=536,542) | 0.2 | 0.0 |
| non-SAEs at 13vPnC (Year 5)(n=364,363) | 4.7 | 3.6 |
| non-SAEs at 6-month follow-up (Year 5)(n=364,363) | 0.3 | 68.3 |
Collected over AEs/SAEs recorded: All AEs for 1 month postvaccination. All SAEs and newly diagnosed chronic medical conditions for 6 months postvaccination. Deaths and withdrawals due to S/AE in Years 1-4. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC+TIV/Placebo: Dose 1 (Year 0) | — | 4/551 (0.7%) | 420/551 (76.2%) |
| 13vPnC+TIV/Placebo: Dose 2 (Year 0) | — | 3/538 (0.6%) | 248/538 (46.1%) |
| 13vPnC+TIV/Placebo: 6 Month Follow-up (Year 0) | — | 18/538 (3.3%) | 26/538 (4.8%) |
| 13vPnC+TIV/Placebo: Years 1-4 | — | 8/536 (1.5%) | 1/536 (0.2%) |
| 13vPnC+TIV/Placebo: 13vPnC (Year 5) | — | 2/364 (0.5%) | 256/364 (70.3%) |
| 13vPnC+TIV/Placebo: 6 Month Follow-up (Year 5) | — | 2/364 (0.5%) | 1/364 (0.3%) |
| Placebo+TIV/13vPnC: Dose 1 (Year 0) | — | 5/560 (0.9%) | 326/560 (58.2%) |
| Placebo+TIV/13vPnC: Dose 2 (Year 0) | — | 6/543 (1.1%) | 388/543 (71.5%) |
| Placebo+TIV/13vPnC: 6 Month Follow-up (Year 0) | — | 10/543 (1.8%) | 29/543 (5.3%) |
| Placebo+TIV/13vPnC: Years 1-4 | — | 3/542 (0.6%) | 0/542 (0%) |
| Placebo+TIV/13vPnC: 13vPnC (Year 5) | — | 2/363 (0.6%) | 248/363 (68.3%) |
| Placebo+TIV/13vPnC: 6 Month Follow-up (Year 5) | — | 3/363 (0.8%) | 0/363 (0%) |
| Event | 13vPnC+TIV/Placebo: Dose 1 (Year 0) | 13vPnC+TIV/Placebo: Dose 2 (Year 0) | 13vPnC+TIV/Placebo: 6 Month Follow-up (Year 0) | 13vPnC+TIV/Placebo: Years 1-4 | 13vPnC+TIV/Placebo: 13vPnC (Year 5) | 13vPnC+TIV/Placebo: 6 Month Follow-up (Year 5) | Placebo+TIV/13vPnC: Dose 1 (Year 0) | Placebo+TIV/13vPnC: Dose 2 (Year 0) | Placebo+TIV/13vPnC: 6 Month Follow-up (Year 0) | Placebo+TIV/13vPnC: Years 1-4 | Placebo+TIV/13vPnC: 13vPnC (Year 5) | Placebo+TIV/13vPnC: 6 Month Follow-up (Year 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/551 | 0/538 | 1/538 | 2/536 | 0/364 | 0/364 | 1/560 | 0/543 | 0/543 | 0/542 | 0/363 | 0/363 |
| DiverticulitisInfections and infestations | 0/551 | 0/538 | 2/538 | 0/536 | 0/364 | 0/364 | 0/560 | 0/543 | 1/543 | 0/542 | 0/363 | 0/363 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/551 | 0/538 | 2/538 | 0/536 | 0/364 | 0/364 | 0/560 | 0/543 | 0/543 | 0/542 | 0/363 | 1/363 |
| Renal colicRenal and urinary disorders | 0/551 | 0/538 | 0/538 | 0/536 | 0/364 | 0/364 | 0/560 | 0/543 | 0/543 | 0/542 | 0/363 | 1/363 |
| ThrombosisVascular disorders | 1/551 | 0/538 | 0/538 | 0/536 | 0/364 | 0/364 | 0/560 | 0/543 | 0/543 | 0/542 | 1/363 | 0/363 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/551 | 0/538 | 1/538 | 0/536 | 0/364 | 0/364 | 0/560 | 1/543 | 0/543 | 0/542 | 0/363 | 1/363 |
| Clostridium difficile infectionInfections and infestations | 0/551 | 0/538 | 0/538 | 0/536 | 0/364 | 0/364 | 0/560 | 0/543 | 0/543 | 0/542 | 1/363 | 0/363 |
| Uterine prolapseReproductive system and breast disorders | 0/551 | 0/538 | 0/538 | 0/536 | 1/364 | 0/364 | 0/560 | 0/543 | 0/543 | 0/542 | 0/363 | 0/363 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/551 | 0/538 | 0/538 | 0/536 | 0/364 | 1/364 | 0/560 | 0/543 | 0/543 | 0/542 | 0/363 | 0/363 |
| Spinal column stenosisMusculoskeletal and connective tissue disorders | 0/551 | 0/538 | 0/538 | 0/536 | 1/364 | 0/364 | 0/560 | 1/543 | 0/543 | 0/542 | 0/363 | 0/363 |
| Event | 13vPnC+TIV/Placebo: Dose 1 (Year 0) | 13vPnC+TIV/Placebo: Dose 2 (Year 0) | 13vPnC+TIV/Placebo: 6 Month Follow-up (Year 0) | 13vPnC+TIV/Placebo: Years 1-4 | 13vPnC+TIV/Placebo: 13vPnC (Year 5) | 13vPnC+TIV/Placebo: 6 Month Follow-up (Year 5) | Placebo+TIV/13vPnC: Dose 1 (Year 0) | Placebo+TIV/13vPnC: Dose 2 (Year 0) | Placebo+TIV/13vPnC: 6 Month Follow-up (Year 0) | Placebo+TIV/13vPnC: Years 1-4 | Placebo+TIV/13vPnC: 13vPnC (Year 5) | Placebo+TIV/13vPnC: 6 Month Follow-up (Year 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any local reactionSkin and subcutaneous tissue disorders | 420/474 | 105/300 | 0/538 | 0/536 | 256/315 | 0/364 | 128/325 | 388/456 | 0/543 | 0/542 | 248/308 | 0/363 |
| Pain: AnySkin and subcutaneous tissue disorders | 407/469 | 94/294 | 0/538 | 0/536 | 248/313 | 0/364 | 119/321 | 383/453 | 0/543 | 0/542 | 243/306 | 0/363 |
| Any systemic eventGeneral disorders | 417/484 | 248/381 | 0/538 | 0/536 | 221/307 | 0/364 | 326/430 | 326/425 | 0/543 | 0/542 | 218/290 | 0/363 |
| Pain: MildSkin and subcutaneous tissue disorders | 380/459 | 89/290 | 0/538 | 0/536 | 227/297 | 0/364 | 112/318 | 354/431 | 0/543 | 0/542 | 224/299 | 0/363 |
| Headache: anyGeneral disorders | 263/399 | 161/334 | 0/538 | 0/536 | 120/256 | 0/364 | 216/382 | 172/338 | 0/543 | 0/542 | 127/248 | 0/363 |
| New muscle pain: anyGeneral disorders | 252/385 | 82/288 | 0/538 | 0/536 | 127/266 | 0/364 | 123/326 | 207/350 | 0/543 | 0/542 | 129/253 | 0/363 |
| Fatigue: anyGeneral disorders | 226/389 | 138/316 | 0/538 | 0/536 | 115/263 | 0/364 | 188/359 | 175/338 | 0/543 | 0/542 | 115/251 | 0/363 |
| Limitation of arm movement: AnySkin and subcutaneous tissue disorders | 113/317 | 23/248 | 0/538 | 0/536 | 54/233 | 0/364 | 24/270 | 135/318 | 0/543 | 0/542 | 59/224 | 0/363 |
| Limitation of arm movement: MildSkin and subcutaneous tissue disorders | 101/310 | 23/248 | 0/538 | 0/536 | 52/233 | 0/364 | 22/268 | 130/316 | 0/543 | 0/542 | 50/219 | 0/363 |
| Pain: ModerateSkin and subcutaneous tissue disorders | 127/324 | 11/243 | 0/538 | 0/536 | 81/248 | 0/364 | 11/261 | 131/319 | 0/543 | 0/542 | 82/235 | 0/363 |
Safety analysis set included all randomized participants who had received at least 1 dose of study treatment.
| Age, Continuous(years) | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) | Total |
|---|---|---|---|
| Mean | 54.6 ± 2.8 | 54.6 ± 2.9 | 54.6 ± 2.8 |
| Sex: Female, Male(Participants) | 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) | Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) | Total |
|---|---|---|---|
| Female | 319 | 322 | 641 |
| Male | 232 | 238 | 470 |
The record gives a start of Sep 2007, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine